Precipio (PRPO) 10-K 30 Mar 23 2022 FY Annual report Financial data

DOCUMENT AND ENTITY INFORMATION

DOCUMENT AND ENTITY INFORMATION - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Mar. 28, 2023	Jun. 30, 2022
Document and Entity Information [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2022
Document Transition Report	false
Entity File Number	001-36439
Entity Registrant Name	PRECIPIO, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	91-1789357
Entity Address, Address Line One	4 Science Park
Entity Address, City or Town	New Haven
Entity Address, State or Province	CT
Entity Address, Postal Zip Code	06511
City Area Code	203
Local Phone Number	787-7888
Title of 12(b) Security	Common Stock
Trading Symbol	PRPO
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 23.3
Entity Common Stock, Shares Outstanding		23,353,893
ICFR Auditor Attestation Flag	false
Auditor Name	Marcum LLP
Auditor Firm ID	688
Auditor Location	New Haven, CT
Entity Central Index Key	0001043961
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Amendment Flag	false

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Dec. 31, 2022	Dec. 31, 2021
CURRENT ASSETS:
Cash	$ 3,445,000	$ 11,668,000
Accounts receivable, net	1,036,000	697,000
Inventories	708,000	564,000
Other current assets	521,000	549,000
Total current assets	5,710,000	13,478,000
PROPERTY AND EQUIPMENT, NET	877,000	836,000
OTHER ASSETS:
Finance lease right-of-use assets, net	257,000	371,000
Operating lease right-of-use assets, net	763,000	858,000
Intangibles, net	13,768,000	14,717,000
Other assets	129,000	179,000
Total assets	21,504,000	30,439,000
CURRENT LIABILITIES:
Current maturities of long-term debt, less debt issuance costs	255,000	26,000
Current maturities of finance lease liabilities	162,000	222,000
Current maturities of operating lease liabilities	199,000	166,000
Accounts payable	2,042,000	1,863,000
Accrued expenses	1,584,000	1,918,000
Deferred revenue	119,000	18,000
Total current liabilities	4,361,000	4,213,000
LONG TERM LIABILITIES:
Long-term debt, less current maturities and debt issuance costs	134,000	160,000
Finance lease liabilities, less current maturities	68,000	159,000
Operating lease liabilities, less current maturities	574,000	697,000
Common stock warrant liabilities		606,000
Total liabilities	5,137,000	5,835,000
COMMITMENTS AND CONTINGENCIES (Note 5)
STOCKHOLDERS' EQUITY:
Preferred stock - $0.01 par value, 15,000,000 shares authorized at December 31, 2022 and December 31, 2021, 47 shares issued and outstanding at December 31, 2022 and December 31, 2021, liquidation preference of $64 at December 31, 2022
Common stock, $0.01 par value, 150,000,000 shares authorized at December 31, 2022 and December 31, 2021, 22,820,260 and 22,708,442 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively	228,000	227,000
Additional paid-in capital	108,371,000	104,431,000
Accumulated deficit	(92,297,000)	(80,094,000)
Total Precipio, Inc. stockholders' equity	16,302,000	24,564,000
Noncontrolling interest in joint venture	65,000	40,000
Total stockholders' equity	16,367,000	24,604,000
Total liabilities and stockholders' equity	$ 21,504,000	$ 30,439,000

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) $ in Thousands	Dec. 31, 2022 USD ($) $ / shares shares
CONSOLIDATED BALANCE SHEETS [Abstract]
Preferred stock, par value (in dollars per share) | $ / shares	$ 0.01
Preferred stock, shares authorized (in shares)	15,000,000
Preferred stock, shares issued (in shares)	47
Preferred stock, shares outstanding (in shares)	47
Preferred stock, liquidation preference | $	$ 64
Common stock, par value | $ / shares	$ 0.01
Common stock, shares authorized (in shares)	150,000,000
Common stock, shares issued (in shares)	22,820,260
Common stock, shares outstanding (in shares)	22,820,260

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Revenue, net of contractual allowances and adjustments	$ 9,820	$ 8,697
Adjustment for allowance for doubtful accounts	(408)	152
Net sales	9,412	8,849
Total cost of sales	6,902	6,457
Gross profit	2,510	2,392
OPERATING EXPENSES:
Operating expenses	15,307	12,005
OPERATING LOSS	(12,797)	(9,613)
OTHER INCOME (EXPENSE):
Interest income (expense), net	(12)	(20)
Warrant revaluation	606	269
Gain on settlement of liability	25	53
Gain on forgiveness of Paycheck Protection Program loan		794
Total other income (expense)	619	1,096
LOSS BEFORE INCOME TAXES	(12,178)	(8,517)
INCOME TAX EXPENSE	0	0
NET LOSS	(12,178)	(8,517)
Less: Net income attributable to noncontrolling interest in joint venture	(25)	(13)
NET LOSS ATTRIBUTABLE TO PRECIPIO, INC. COMMON STOCKHOLDERS	$ (12,203)	$ (8,530)
LOSS PER COMMON SHARE, BASIC	$ (0.54)	$ (0.40)
LOSS PER COMMON SHARE, DILUTED	$ (0.54)	$ (0.40)
WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING, BASIC	22,751,460	21,098,197
WEIGHTED-AVERAGE SHARES OF COMMON STOCK OUTSTANDING, DILUTED	22,751,460	21,098,197
Service revenue, net [Member]
Revenue, net of contractual allowances and adjustments	$ 8,418	$ 7,783
Adjustment for allowance for doubtful accounts	(408)	152
Net sales	8,010	7,935
Total cost of sales	5,917	5,496
Other [Member]
Revenue, net of contractual allowances and adjustments	1,402	914
Net sales	1,402	914
Total cost of sales	$ 985	$ 961

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total Precipio, Inc. [Member]	Noncontrolling Interest in Joint Venture [Member]	Total
Balance at beginning of period at Dec. 31, 2020		$ 176	$ 85,523	$ (71,564)	$ 14,135	$ 27	$ 14,162
Balance at beginning of period (in shares) at Dec. 31, 2020	47	17,576,916
Increase (Decrease) in Stockholders' Equity
Net loss				(8,530)	(8,530)	13	(8,517)
Issuance of common stock in connection with purchase agreements		$ 5	1,255		1,260		1,260
Issuance of common stock in connection with purchase agreements (in shares)		500,000
Issuance of common stock in connection with at the market offering, net of issuance costs		$ 45	14,902		14,947		14,947
Issuance of common stock in connection with at the market offering, net of issuance costs (in shares)		4,501,000
Proceeds upon issuance of common stock from exercise of warrants		$ 1	399		400		400
Proceeds upon issuance of common stock from exercise of warrants (in shares)		74,000
Proceeds upon issuance of common stock from exercise of stock options			3		3		3
Proceeds upon issuance of common stock from exercise of stock options (in shares)		1,379
Write-off warrant liability in conjunction with warrant exercises			320		320		320
Issuance of common stock for consulting services			150		150		150
Issuance of common stock for consulting services (in shares)		55,147
Stock-based compensation			1,879		1,879		1,879
Balance at end of period at Dec. 31, 2021		$ 227	104,431	(80,094)	24,564	40	24,604
Balance at end of period (in shares) at Dec. 31, 2021	47	22,708,442
Balance at beginning of period at Dec. 31, 2020		$ 176	85,523	(71,564)	14,135	27	14,162
Balance at beginning of period (in shares) at Dec. 31, 2020	47	17,576,916
Balance at end of period at Dec. 31, 2022		$ 228	108,371	(92,297)	16,302	65	16,367
Balance at end of period (in shares) at Dec. 31, 2022	47	22,820,260
Balance at beginning of period at Dec. 31, 2021		$ 227	104,431	(80,094)	24,564	40	24,604
Balance at beginning of period (in shares) at Dec. 31, 2021	47	22,708,442
Increase (Decrease) in Stockholders' Equity
Net loss				(12,203)	(12,203)	25	(12,178)
Issuance of common stock in connection with at the market offering, net of issuance costs		$ 1	128		129		129
Issuance of common stock in connection with at the market offering, net of issuance costs (in shares)		85,023
Proceeds upon issuance of common stock from exercise of warrants			11		11		11
Proceeds upon issuance of common stock from exercise of warrants (in shares)		26,795
Stock-based compensation			3,801		3,801		3,801
Balance at end of period at Dec. 31, 2022		$ 228	$ 108,371	$ (92,297)	$ 16,302	$ 65	$ 16,367
Balance at end of period (in shares) at Dec. 31, 2022	47	22,820,260

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (12,178)	$ (8,517)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation and amortization	1,219	1,131
Amortization of operating lease right-of-use asset	187	219
Amortization of finance lease right-of-use asset	114	94
Amortization of deferred financing costs, debt discounts and debt premiums	4	3
Gain on forgiveness of debt		(794)
Gain on settlement of liability	(25)	(53)
Stock-based compensation	3,801	1,879
Value of stock issued in payment of services		150
Provision for losses on doubtful accounts	406	(150)
Warrant revaluation	(606)	(269)
Derecognition of finance lease right-of-use asset		125
Changes in operating assets and liabilities:
Accounts receivable	(745)	327
Inventories	(144)	(214)
Other assets	491	(349)
Accounts payable	165	112
Operating lease liabilities	(182)	(225)
Deferred revenue	101	12
Accrued expenses	(329)	(58)
Net cash used in operating activities	(7,721)	(6,577)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(277)	(682)
Net cash used in investing activities	(277)	(682)
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments on finance lease obligations	(151)	(130)
Deposits on finance lease right-of-use assets		(39)
Issuance of common stock, net of issuance costs	129	16,207
Proceeds from exercise of warrants	11	400
Proceeds from exercise of stock options		3
Principal payments on long-term debt	(214)	(40)
Payments on common stock warrant liabilities		(130)
Net cash flows (used in) provided by financing activities	(225)	16,271
NET CHANGE IN CASH	(8,223)	9,012
CASH AT BEGINNING OF PERIOD	11,668	2,656
CASH AT END OF PERIOD	3,445	11,668
SUPPLEMENTAL CASH FLOW INFORMATION
Cash paid during the period for interest	45	34
SUPPLEMENTAL DISCLOSURE OF CONSULTING SERVICES OR ANY OTHER NON-CASH COMMON STOCK RELATED ACTIVITY
Purchases of equipment financed through accounts payable	34	58
Prepaid insurance financed with loan	413
Operating lease right-of-use assets obtained in exchange for operating lease obligations	92	771
Finance lease right-of-use assets obtained in exchange for finance lease obligations	$ 12	347
Write-off warrant liability in conjunction with warrant exercises		$ 320

BUSINESS DESCRIPTION

BUSINESS DESCRIPTION	12 Months Ended
	Dec. 31, 2022
BUSINESS DESCRIPTION [Abstract]
BUSINESS DESCRIPTION	PRECIPIO, INC. AND SUBSIDIARIES NOTES TO CONSOLIDATED FINANCIAL STATEMENTS For the Years Ended December 31, 2022 and 2021 1. BUSINESS DESCRIPTION Business Description. Precipio, Inc., and its subsidiaries, (collectively, “we”, “us”, “our”, the “Company” or “Precipio”) is a healthcare solutions company focused on cancer diagnostics. The Company’s business mission is to address the pervasive problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents and services. Misdiagnoses originate from aged commercial diagnostic cancer testing technologies, lack of subspecialized expertise, and sub-optimal laboratory processes that are needed in today’s diagnostic cancer testing in order to provide accurate, rapid, and resource-effective results to treat patients. Industry studies estimate 1 in 5 blood-cancer patients are misdiagnosed. As cancer diagnostic testing has evolved from cellular to molecular (genes and exons), laboratory testing has become extremely complex, requiring even greater diagnostic precision, attention to process and a more appropriate evaluation of the abundance of genetic data to effectively gather, consider, analyze and present information for the physician for patient treatment. Precipio sees cancer diagnostics as requiring a holistic approach to improve diagnostic data for improved interpretations with the intent to reduce misdiagnoses. By delivering diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, leading to fewer misdiagnoses, we believe patient outcomes can be improved through the selection of appropriate therapeutic options. Furthermore, we believe that better patient outcomes will have a positive impact on healthcare expenses as misdiagnoses are reduced. Better Diagnostic Results – Better Patient Outcome – Lower Healthcare Expenditures. ​ To deliver its strategy, the Company has structured its organization in order to drive development of diagnostic products. Laboratory and R&D facilities located in New Haven, Connecticut and Omaha, Nebraska house development teams that collaborate on new products and services. The Company operates CLIA laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. To deliver on our strategy of mitigating misdiagnoses we rely heavily on our CLIA laboratory to support R&D beta-testing of the products we develop, in a clinical environment. ​ Our operating structure promotes the harnessing of our proprietary technology and genetic diagnostic expertise to bring to market the Company’s robust pipeline of innovative solutions designed to address the root causes of misdiagnoses. ​ Joint Venture. In April 2020, the Company formed a joint venture with Poplar Healthcare PLLC (“Poplar”), which we refer to as the “Joint Venture”. The Joint Venture was formed by the Limited Liability Company Agreement of Precipio Oncometrix LLC, a Delaware limited liability company (“POC”), which was entered into as of April 11, 2020 (the “Effective Date”), by and among POC, Poplar, and Precipio SPV Inc. (“Precipio SPV”), a newly formed subsidiary of the Company, together with such other persons who from time to time become party to the Limited Liability Company Agreement by executing a counterpart signature page in accordance with the terms hereof. POC was formed as a limited liability company on April 2, 2020 in accordance with the statutes and laws of the State of Delaware relating to limited liability companies. Precipio SPV was incorporated in the State of Delaware on March 10, 2020 for the sole purpose of being a party to the Joint Venture. ​ Under the terms of the Joint Venture, Precipio SPV has a 49% ownership interest in the Joint Venture, with Poplar having a 51 % ownership. Pursuant to the Limited Liability Company Agreement, Poplar, at any time, has the right to require Precipio SPV to purchase all, but not less than all, of Poplar’s shares in the Joint Venture (the “Poplar Put Right”). The purchase price for Poplar’s shares shall be $1.00 per share, or fifty-one dollars, and Precipio SPV would, therefore, become the sole 100% owner of the Joint Venture at the time the Poplar Put Right became effective. The Company has determined that it holds a variable interest in the Joint Venture and is the primary beneficiary of the variable interest entity (“VIE”). See Note 2 - Summary of Significant Accounting Policies for further discussion regarding consolidation of variable interest entities. The business purpose of the Joint Venture is to facilitate and capitalize on the combined capabilities, resources and healthcare industry relationships of its members by partnering, promoting and providing oncology services to office based physicians, hospitals and medical centers. Operational services of the Joint Venture are performed entirely by its members and employees of its members. Precipio SPV’s responsibilities include product and account management services, selling & marketing, laboratory diagnostic services and general & administrative services. Precipio SPV is entitled to a management fee for the services it provides. This management fee is established through service agreements which were executed in conjunction with the formation of the Joint Venture. Poplar receives a similar fee for the billing services that it provides. ​ The Company is working with Poplar to dissolve the Joint Venture with an effective date of December 31, 2022. ​ Going Concern. The consolidated financial statements have been prepared using accounting principles generally accepted in the United States of America (“GAAP”) applicable for a going concern, which assume that the Company will realize its assets and discharge its liabilities in the ordinary course of business. The Company has incurred substantial operating losses and has used cash in its operating activities for the past several years. For the year ended December 31, 2022, the Company had a net loss of $12.2 million and net cash used in operating activities of $7.7 million. As of December 31, 2022, the Company had an accumulated deficit of $92.3 million and working capital of $1.3 million. The Company’s ability to continue as a going concern, for the next twelve months from the date of issuance of these consolidated financial statements in this Annual Report on Form 10-K, is dependent upon a combination of achieving its business plan, including generating additional revenue and avoiding potential business disruption due to the novel coronavirus (“COVID-19”) pandemic, and raising additional financing to meet its debt obligations and paying liabilities arising from normal business operations when they come due. To meet its current and future obligations the Company has taken the following steps to capitalize the business and successfully achieve its business plan: ● On April 2, 2021, the Company entered into a sales agreement with A.G.P./Alliance Global Partners (“AGP”), pursuant to which the Company may offer and sell its common stock having aggregate sales proceeds of up to $22.0 million, to or through AGP, as sales agent (the “AGP Sales Agreement”). From April 2, 2021 through the date the consolidated financial statements were issued, we have already received approximately $16.0 million in gross proceeds through the AGP Sales Agreement from the sale of 5,119,656 shares of common stock, leaving the Company an additional $6.0 million available for future sales pursuant to the AGP Sales Agreement. Notwithstanding the aforementioned circumstances, there remains substantial doubt about the Company’s ability to continue as a going concern for the next twelve months from the date these consolidated financial statements were available to be issued. There can be no assurance that the Company will be able to successfully achieve its initiatives summarized above in order to continue as a going concern over the next twelve months from the date of issuance of this Annual Report Form 10-K

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2022
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Principles of Consolidation. The consolidated financial statements include the accounts of Precipio, Inc. and our wholly owned subsidiaries, and the Joint Venture which is a VIE in which we are the primary beneficiary. Refer to the section titled “Consolidation of Variable Interest Entities” for further information related to our accounting for the Joint Venture. All inter-company balances and transactions have been eliminated in consolidation. Use of Estimates. The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of net sales and expenses during the reporting period. The most significant estimates and assumptions with regard to these consolidated financial statements relate to the allowance for doubtful accounts, assumptions used within the fair value of debt and equity transactions and contractual allowances. These assumptions require considerable judgment by management. Actual results could differ from the estimates and assumptions used in preparing these consolidated financial statements. Risks and Uncertainties. Certain risks and uncertainties are inherent in our day-to-day operations and in the process of preparing our financial statements. The risks and uncertainties may be heightened by the COVID-19 pandemic and any worsening of the global business and economic environment as a result. The more significant of those risks are presented below and throughout the notes to the consolidated financial statements. The Company operates in the healthcare industry which is subject to numerous laws and regulations of federal, state and local governments. These laws and regulations include, but are not necessarily limited to, matters such as licensure, accreditation, government healthcare program participation requirements, reimbursement for patient services, and Medicare and Medicaid fraud and abuse. Government activity has increased with respect to investigations and allegations concerning possible violations of fraud and abuse statutes and regulations by healthcare providers. Violations of these laws and regulations could result in expulsion from government healthcare programs together with the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed. Management believes that the Company is in compliance with fraud and abuse regulations, as well as other applicable government laws and regulations. While no material regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation as well as regulatory actions unknown or unasserted at this time. Fair Value. Unless otherwise specified, book value approximates fair value. The common stock warrant liabilities are recorded at fair value. See Note 11 - Fair Value for additional information. Other Current Assets. Other current assets of $0.5 million as of December 31, 2022 include prepaid insurance of approximately $0.3 million and prepaid and other assets of $0.2 million. Other current assets of $0.5 million as of December 31, 2021 include prepaid insurance of $0.3 million and prepaid and other assets of $0.2 million. Concentrations of Risk. From time to time, we may maintain a cash position with financial institutions in amounts that exceed Federal Deposit Insurance Corporation insured limits of up to $250,000 per depositor per financial institution. We have not experienced any losses on such accounts as of December 31, 2022. Service companies in the health care industry typically grant credit without collateral to patients. The majority of these patients are insured under third-party insurance agreements. The services provided by the Company are routinely billed utilizing the Current Procedural Terminology (CPT) code set designed to communicate uniform information about medical services and procedures among physicians, coders, patients, accreditation organizations, and payers for administrative, financial, and analytical purposes. CPT codes are currently identified by the Centers for Medicare and Medicaid Services and third-party payers. The Company utilizes CPT codes for Pathology and Laboratory Services contained within codes 80000-89398. Inventories. Inventories consist of laboratory supplies and are valued at cost (determined on an average cost basis, which approximates the first-in, first-out method) or net realizable value, whichever is lower. We evaluate inventory for items that are slow moving or obsolete and record an appropriate reserve for obsolescence if needed. We have an allowance for slow moving or obsolete inventory of zero and less than $0.1 million at December 31, 2022 and 2021, respectively. Property and Equipment, net. Property and equipment are carried at cost, net of accumulated depreciation and amortization. Expenditures for maintenance and repairs are expensed as incurred. Depreciation and amortization are computed by the straight-line method over the estimated useful lives of the related assets as follows: ​ ​ ​ ​ Furniture and fixtures 5 to 7 years Laboratory equipment 3 to 10 years Computer equipment and software 3 to 7 years ​ For assets sold or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the accounts, and any related gain or loss is reflected in operations for the period. Expenditures for major betterments that extend the useful lives of property and equipment are capitalized. Intangible Assets. We review our amortizable long-lived assets for impairment annually or whenever events indicate that the carrying amount of the asset (group) may not be recoverable. An impairment loss may be needed if the sum of the future undiscounted cash flows is less than the carrying amount of the asset (group). The amount of the loss would be determined by comparing the fair value of the asset to the carrying amount of the asset (group). There were no impairment charges on our amortizable long-lived assets during the years ended December 31, 2022 and 2021. Debt Issuance Costs Debt issuance costs are being amortized over the lives of the related financings on a basis that approximates the effective interest method. Costs are presented as a reduction of the related debt in the accompanying balance sheets. The amortization expense recorded was less than $0.1 million for the years ended December 31, 2022 and 2021, respectively. See Note 5 – Long Term Debt for further discussion. Stock-Based Compensation. All stock-based awards to date have exercise prices equal to the market price of our common stock on the date of grant and have ten-year contractual terms. Stock-based compensation cost is based on the fair value of the portion of stock-based awards that is ultimately expected to vest. The Company utilizes the Black-Scholes option pricing model for determining the estimated fair value for stock-based awards. Unvested awards as of December 31, 2022 had vesting periods of up to four years from the date of grant. No awards outstanding at December 31, 2022 and 2021, respectively, are subject to performance vesting conditions or market-based vesting. Net Sales Recognition. Revenue recognition occurs when a customer obtains control of the promised goods and service. Revenue assigned to the goods and services reflects the consideration which the Company expects to receive in exchange for those goods and services. ​ The Company derives its revenues from diagnostic testing - histology, flow cytometry, cytology and molecular testing; clinical research from bio-pharma customers, state and federal grant programs; biomarker testing from bio-pharma customers and from other product sales including revenues from equipment leases and reagent sales associated with our HSRR program ​ The Company recognizes revenue utilizing the five-step framework of ASC 606. Control of the laboratory testing services is transferred to the customer at a point in time. As such, the Company recognizes revenue for diagnostic testing at a point in time based on the delivery method (web-portal access or fax) for a patient’s laboratory report. Diagnostic testing service revenue is reported at the estimated net realizable amounts from patients, third-party payers and others for services rendered, including retroactive adjustment under reimbursement agreements with third-party payers. Provisions for third-party payer settlements are provided in the period in which the related services are rendered and adjusted in the future periods, as final settlements are determined. For clinical research and biomarker services, the Company utilizes an “effort based” method of assessing performance and measures progress towards satisfaction of the performance obligation based upon the delivery of results per the contract. Control of reagents and other diagnostic products are transferred to the customer at a point in time and, as such, the Company recognizes these revenues at a point in time based on the delivery method. When we receive payment in advance, we initially defer the revenue and recognize it when we deliver the service. ​ Taxes collected from customers and remitted to government agencies for specific net sales producing transactions are recorded net with no effect on the statements of operations. Accounts Receivable Accounts Receivable result from diagnostic services provided to self-pay and insured patients, project based testing services and clinical research. The payment for services provided by the Company are generally due within 30 days from the invoice date. Accounts receivable are reduced by an allowance for doubtful accounts. In evaluating the collectability of accounts receivable, the Company analyzes and identifies trends for each of its sources of revenue to estimate the appropriate allowance for doubtful accounts. For receivables associated with self-pay patients, including patients with insurance and a deductible and copayment, the Company records an allowance for doubtful accounts in the period of services on the basis of past experience of patients unable or unwilling to pay for service fee for which they are financially responsible. For receivables associated with services provided to patients with third-party coverage, the Company analyzes contractually due amounts and provides an allowance, if necessary. The difference between the standard rates and the amounts actually collected after all reasonable collection efforts have been exhausted is charged against the allowance for doubtful accounts. Presentation of Insurance Claims and Related Insurance Recoveries. The Company accounts for its insurance claims and related insurance recoveries at their gross values as standards for health care entities do not allow the Company to net insurance recoveries against the related claim liabilities. There were no insurance claims or insurance recoveries recorded during the years ended December 31, 2022 and 2021. Advertising Costs. Advertising costs are expensed as incurred and are included in operating expenses on the consolidated statements of operations. Advertising costs charged to operations totaled approximately $0.1 million in 2022 and 2021, respectively. Research and Development Costs. All costs associated with internal research and development are expensed as incurred. These costs include salaries and employee related expenses, operating supplies and facility-related expenses. Research and development costs charged to operations totaled $1.7 million and $1.3 million for the years ended December 31, 2022 and 2021, respectively. Income Taxes. Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities at each balance sheet date using tax rates expected to be in effect in the year the differences are expected to reverse. The effect on the deferred tax assets and liabilities of a change in tax rates is recognized in the period when the change in tax rates is enacted. A valuation allowance is established when it is determined that it is more likely than not that some portion or all of the deferred tax assets will not be realized. A full valuation allowance has been applied against the Company’s net deferred tax assets as of December 31, 2022 and 2021, due to projected losses and because it is not more likely than not that the Company will realize future benefits associated with these deferred tax assets. Management’s conclusions regarding uncertain tax positions may be subject to review and adjustment at a later date based upon ongoing analysis of, or changes in tax laws, regulations and interpretations thereof as well as other factors. The Company’s policy is to record interest and penalties directly related to income taxes as income tax expense in the accompanying consolidated statements of operations, of which there was none for the years ended December 31, 2022 and 2021. Common Stock Warrants. The Company classifies the issuance of common stock warrants as equity any contracts that (i) require physical settlement or net-stock settlement or (ii) gives the Company a choice of net-cash settlement or settlement in its own stocks (physical settlement or net-stock settlement). The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is outside of the Company’s control), or (ii) gives the counterparty a choice of net-cash settlement or settlement in stock (physical settlement or net-stock settlement). Certain of our issued and outstanding warrants to purchase common stock do not qualify to be treated as equity and accordingly, are recorded as a liability (“Common Stock Warrant Liability”). We are required to present these instruments at fair value at each reporting date and any changes in fair values are recorded as an adjustment to earnings. Consolidation of Variable Interest Entities. We evaluate any entity in which we are involved to determine if the entity is a VIE and if so, whether we hold a variable interest and are the primary beneficiary. We consolidate VIEs that are subject to assessment when we are deemed to be the primary beneficiary of the VIE. The process for determining whether we are the primary beneficiary of the VIE is to conclude whether we are a party to the VIE holding a variable interest that meets both of the following criteria: (1) has the power to make decisions that most significantly affect the economic performance of the VIE, and (2) has the obligation to absorb losses or the right to receive benefits that in either case could potentially be significant to the VIE. We have determined that we hold a variable interest in the Joint Venture, have the power to make significant operational decisions on behalf of the VIE and also have the obligation to absorb the majority of the losses from the VIE. As such we have also determined that we are the primary beneficiary of the VIE. The following table presents information about the carrying value of the assets and liabilities of the Joint Venture which we consolidate and which are included on our consolidated balance sheets. Intercompany balances are eliminated in consolidation and not reflected in the following table. ​ ​ ​ ​ ​ ​ ​ (dollars in thousands) December 31, 2022 December 31, 2021 Assets: ​ ​ ​ ​ ​ ​ Accounts receivable, net ​ $ 335 ​ $ 180 Total assets ​ $ 335 ​ $ 180 Liabilities: ​ ​ ​ ​ ​ ​ Accrued expenses ​ $ 50 ​ $ 36 Total liabilities ​ $ 50 ​ $ 36 Noncontrolling interest in Joint Venture ​ $ 65 ​ $ 40 Total stockholders' equity ​ $ 127 ​ $ 79 ​ Loss Per Share. Basic loss per share is calculated based on the weighted-average number of common shares outstanding during each period. Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock. Options, warrants and conversion rights pertaining to 4,487,967 and 3,584,688 shares of our common stock have been excluded from the computation of diluted loss per share at December 31, 2022 and 2021, respectively, because the effect is anti-dilutive due to the net loss. The following table summarizes the outstanding securities not included in the computation of diluted net loss per share: ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Stock options 3,681,336 2,635,287 Warrants 689,131 831,901 Preferred stock 117,500 117,500 Total 4,487,967 3,584,688 ​ Recently Adopted Accounting Pronouncements. In July 2021, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2021-05, Lease (Topic 842), “Lessors - Certain Leases with Variable Lease Payments” In May 2021, the FASB issued ASU 2021-04, “ Issuer s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options” ​ Recent Accounting Pronouncements Not Yet Adopted. In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820) (“ASU 2022-03”). The amendments in ASU 2022-03 clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendments also clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The amendments in this Update also require additional disclosures for equity securities subject to contractual sale restrictions. The provisions in this Update are effective for fiscal years beginning after December 15, 2023. Early adoption is permitted. The Company does not expect to early adopt this ASU. The Company is currently assessing the potential impact that the adoption of this ASU will have on its consolidated financial statements. In August 2020, the FASB issued ASU 2020-06 “ Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity In June 2016, the FASB issued ASU 2016-13 “ Measurement of Credit Losses on Financial Instruments ​ Reclassification. Certain reclassifications were made to the statements of cash flows related to splitting accruals and deferred revenue to separate lines in order to conform to the 2022 presentation. These reclassifications had no effect on previously reported retained earnings, net income, total assets or liabilities, or cash flows used in operating activities.

PROPERTY AND EQUIPMENT, NET

PROPERTY AND EQUIPMENT, NET	12 Months Ended
	Dec. 31, 2022
PROPERTY AND EQUIPMENT, NET [Abstract]
PROPERTY AND EQUIPMENT, NET	3 A summary of property and equipment at December 31, 2022 and 2021 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ 2022 2021 Furniture and fixtures and leasehold improvements ​ $ 24 ​ $ 12 Laboratory equipment ​ 931 ​ 794 Computer equipment and laboratory software ​ 990 ​ 725 Construction in process ​ 34 ​ 138 ​ ​ 1,979 ​ 1,669 Less—accumulated depreciation and amortization ​ (1,102) ​ (833) Total ​ $ 877 ​ $ 836 ​ Depreciation expense was approximately $0.3 million and $0.2 million for the years ended December 31, 2022 and 2021, respectively.

INTANGIBLES

INTANGIBLES	12 Months Ended
	Dec. 31, 2022
INTANGIBLES [Abstract]
INTANGIBLES	4 Intangible assets consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Dollars in Thousands ​ ​ December 31, 2022 ​ ​ ​ Accumulated Net Book ​ ​ Cost ​ Amortization ​ Value Technology ​ $ 18,990 ​ $ 5,222 ​ $ 13,768 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Dollars in Thousands ​ ​ December 31, 2021 ​ ​ ​ Accumulated Net Book ​ ​ Cost ​ Amortization ​ Value Technology ​ $ 18,990 ​ $ 4,273 ​ $ 14,717 ​ ​ ​ ​ ​ ​ Estimated Useful Life ​ Technology 20 years ​ Amortization expense for intangible assets was $1.0 million during the years ended December 31, 2022 and 2021, respectively. Amortization expense for intangible assets is expected to be $1.0 million for each of the years ending December 31, 2023, 2024 2025 2026 2027

LONG-TERM DEBT

LONG-TERM DEBT	12 Months Ended
	Dec. 31, 2022
LONG-TERM DEBT [Abstract]
LONG-TERM DEBT	5 Long-term debt consists of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ Dollars in Thousands ​ December 31, 2022 December 31, 2021 Connecticut Department of Economic and Community Development (DECD) ​ $ 176 ​ $ 205 DECD debt issuance costs ​ (15) ​ (19) Financed insurance loan ​ 228 ​ — Total long-term debt ​ 389 ​ 186 Current portion of long-term debt ​ (255) ​ (26) Long-term debt, net of current maturities ​ $ 134 ​ $ 160 ​ Department of Economic and Community Development On January 8, 2018, the Company entered into an agreement with DECD ​ Debt issuance costs associated with the DECD 2018 Loan were approximately $31,000. Amortization of the debt issuance cost was approximately $4,000 and $3,000 for the years ended December 31, 2022 and 2021, respectively. Net debt issuance costs were approximately $15,000 and $19,000 at December 31, 2022 and 2021, respectively, and are presented as a reduction of the related debt in the accompanying consolidated balance sheets. Amortization for each of the next five years expected Financed Insurance Loan. The Company finances certain of its insurance premiums (the “Financed Insurance Loans”). In July 2022, the Company financed $0.4 million with a 5.99% interest rate and is obligated to make payments on a monthly basis through June 2023. As of December 31, 2022 and 2021, the Financed Insurance Loan’s outstanding balance of $0.2 million and zero, respectively, was included in current maturities of long-term debt in the Company’s consolidated balance sheets. A corresponding prepaid asset was included in other current assets. Paycheck Protection Program. ​ On April 23, 2020, the Company entered into a promissory note (the “Promissory Note”) evidencing an unsecured $787,200 loan under the Paycheck Protection Program (the “PPP Loan”). The Paycheck Protection Program (or “PPP”) was established under the recently congressionally-approved Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) and is administered by the U.S. Small Business Administration. The PPP Loan to the Company was made through Webster Bank, N.A. On February 11, 2021, the Company filed an application for loan forgiveness with Webster Bank and was subsequently notified by Webster Bank that effective March 24, 2021 the PPP Loan, plus accrued interest, was considered fully forgiven. As a result, the Company recorded a gain on forgiveness of debt of $0.8 million in the consolidated statements of operations for the year ended December 31, 2021. ​ The aggregate future maturities required on gross long-term debt at December 31, 2022 are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2023 2024 2025 2026 2027 2028 and thereafter Total DECD loan ​ $ 30 ​ $ 31 ​ $ 32 ​ $ 33 ​ $ 34 ​ $ 16 ​ $ 176 Financed insurance loan ​ ​ 228 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ 228 ​ ​ $ 258 ​ $ 31 ​ $ 32 ​ $ 33 ​ $ 34 ​ $ 16 ​ $ 404 ​

ACCRUED EXPENSES OTHER CURRENT

ACCRUED EXPENSES OTHER CURRENT LIABILITIES	12 Months Ended
	Dec. 31, 2022
ACCRUED EXPENSES OTHER CURRENT LIABILITIES [Abstract]
ACCRUED EXPENSES OTHER CURRENT LIABILITIES	6 Accrued expenses at December 31, 2022 and 2021 are as follows: ​ ​ ​ ​ ​ ​ ​ (dollars in thousands) 2022 2021 Accrued expenses ​ $ 983 ​ $ 1,033 Accrued compensation ​ 491 ​ 718 Accrued franchise, property and sales and use taxes ​ ​ 91 ​ ​ 148 Accrued interest ​ 19 ​ 19 ​ ​ $ 1,584 ​ $ 1,918 ​ The Company recorded certain settlement reductions in accrued expenses and accounts payable as gains which are included in gain on settlement of liability, net in the consolidated statements of operations. During each of the years ended December 31, 2022 and 2021, approximately $0.1 million, respectively, was recorded as a gain.

LEASES

LEASES	12 Months Ended
	Dec. 31, 2022
LEASES [Abstract]
LEASES	7 The Company leases administrative facilities and laboratory equipment through operating lease agreements. In addition we rent various equipment used in our diagnostic lab and in our administrative offices through finance lease arrangements. Our operating leases include both lease (e.g., fixed payments including rent) and non-lease components (e.g., common area or other maintenance costs). The facility leases include one or more options to renew, from 1 to 5 years or more. The exercise of lease renewal options is typically at our sole discretion, therefore, the renewals to extend the lease terms are not included in our right-of-use (“ROU”) assets and lease liabilities as they are not reasonably certain of exercise. We regularly evaluate the renewal options and, when they are reasonably certain of exercise, we include the renewal period in our lease term. As our leases do not provide an implicit rate, we use our collateralized incremental borrowing rate based on the information available at the lease commencement date in determining the present value of the lease payments. Operating leases result in the recognition of ROU assets and lease liabilities on the balance sheet. ROU assets represent our right to use the leased asset for the lease term and lease liabilities represent our obligation to make lease payments. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Lease expense is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less are not recorded on the balance sheet. The primary leases we enter into with initial terms of 12 months or less are for equipment. On November 29, 2021, we extended the lease term for our office facility in New Haven, Connecticut by modifying the expiration date from December 31, 2021 to December 31, 2026. As a result of this lease extension agreement, on the lease extension date, we recognized an additional operating lease ROU asset and corresponding operating lease liability On May 11, 2022, we extended the lease term for our office facility in Omaha, Nebraska by modifying the expiration date from May 31, 2022 to May 31, 2025. As a result of this lease extension agreement, on the lease extension date, we recognized an additional operating lease ROU asset and corresponding operating lease liability of $0.1 million which equals the present value of the remaining payments due under the lease extension The Company also recognizes ROU assets from finance leases in connection with its HSRR program. For certain customers in the HSRR program, the Company leases diagnostic testing equipment and then subleases the equipment to the customer. Finance lease ROU assets and finance lease liabilities are recognized at the lease commencement date, and at the sublease commencement date the finance lease ROU asset is derecognized and is recorded as cost of sales in the consolidated statements of operations. Derecognized finance lease ROU assets for the years ended December 31, 2022 and 2021 were zero and $0.1 million, respectively. Where Precipio is the lessor, customers lease diagnostic testing equipment from the Company with the transfer of ownership to the customer at the end of the lease term at no additional cost. For these contracts, the Company accounts for the arrangements as sales-type leases. The lease asset for sales-type leases is the net investment in leased asset, which is recorded once the finance lease ROU asset is derecognized and a related gain or loss is noted. The net investment in leased assets was $0.1 million and $0.2 million as of December 31, 2022 and 2021, respectively, and is included in other current assets and other assets in our consolidated balance sheets. The balance sheet presentation of our operating and finance leases is as follows: ​ ​ ​ ​ ​ ​ ​ ​ (dollars in thousands) ​ ​ ​ ​ ​ ​ Classification on the Consolidated Balance Sheet ​ December 31, 2022 ​ December 31, 2021 Assets: ​ ​ ​ ​ ​ ​ Operating lease right-of-use assets, net ​ $ 763 ​ $ 858 Finance lease right-of-use assets, net (1) ​ ​ 257 ​ ​ 371 Total lease assets ​ $ 1,020 ​ $ 1,229 ​ ​ ​ ​ ​ ​ ​ Liabilities: ​ ​ ​ ​ ​ ​ Current: ​ ​ ​ ​ ​ ​ Current maturities of operating lease liabilities ​ $ 199 ​ $ 166 Current maturities of finance lease liabilities ​ ​ 162 ​ ​ 222 Noncurrent: ​ ​ ​ ​ ​ ​ Operating lease liabilities, less current maturities ​ ​ 574 ​ ​ 697 Finance lease liabilities, less current maturities ​ ​ 68 ​ ​ 159 Total lease liabilities ​ $ 1,003 ​ $ 1,244 ​ (1) As of December 31, 2022, the estimated future minimum lease payments, excluding non-lease components, are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (dollars in thousands) Operating Leases ​ Finance Leases ​ Total 2023 ​ $ 252 ​ $ 101 ​ $ 353 2024 ​ 239 ​ 80 ​ 319 2025 ​ 205 ​ 65 ​ 270 2026 ​ 195 ​ ​ 26 ​ 221 Total lease obligations ​ 891 ​ 272 ​ 1,163 Less: Amount representing interest ​ (118) ​ (42) ​ (160) Present value of net minimum lease obligations ​ 773 ​ 230 ​ 1,003 Less, current portion ​ (199) ​ (162) ​ (361) Long term portion ​ $ 574 ​ $ 68 ​ $ 642 ​ ​ Other information as of December 31, 2022 and 2021: ​ ​ ​ ​ ​ ​ December 31, ​ December 31, ​ 2022 ​ 2021 Weighted-average remaining lease term (years): ​ ​ ​ Operating leases 3.7 ​ 4.7 Finance leases 2.8 ​ 3.1 Weighted-average discount rate: ​ ​ ​ Operating leases 8.00% ​ 8.00% Finance leases 10.31% ​ 10.03% ​ During the years ended December 31, 2022 and 2021, operating cash flows from operating leases was $0.2 million, respectively, and operating lease ROU assets obtained in exchange for operating lease liabilities was $0.1 million and $0.8 million, respectively. Operating Lease Costs Operating lease costs were $0.3 million during the years ended December 31, 2022 and 2021, respectively. These costs are primarily related to long-term operating leases for the Company’s facilities and laboratory equipment. Short-term and variable lease costs were less than $0.1 million for the years ended December 31, 2022 and 2021, respectively. Finance Lease Costs Finance lease amortization and interest expenses are included in the consolidated statements of operations for the years ended December 31, 2022 and 2021. The balances within these accounts are approximately $0.1 million, respectively.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2022
COMMITMENTS AND CONTINGENCIES [Abstract]
COMMITMENTS AND CONTINGENCIES	8. COMMITMENTS AND CONTINGENCIES PURCHASE COMMITMENTS The Company has entered into purchase commitments for reagents from suppliers. These agreements started in 2011 and run through 2025. The Company and the suppliers will true up the amounts on an annual basis. The future minimum purchase commitments under these and other purchase agreements are as follows: ​ ​ ​ ​ ​ Years ending December 31, ​ (dollars in thousands) 2023 ​ $ 1,113 2024 ​ 170 2025 ​ 50 ​ ​ $ 1,333 ​ LITIGATIONS The Company is involved in legal proceedings related to matters, which are incidental to its business. Also, the Company is delinquent on the payment of outstanding accounts payable for certain vendors and suppliers who have taken or have threatened to take legal action to collect such outstanding amounts. See below for a discussion on these matters. CPA Global provides us with certain patent management services. On February 6, 2017, CPA Global claimed that we owe approximately $0.2 million for certain patent maintenance services rendered. CPA Global has not filed claims against us in connection with this allegation. A liability of less than $0.1 million has been recorded and is reflected in accounts payable within the accompanying consolidated balance sheets at December 31, 2022 and 2021. LEGAL AND REGULATORY ENVIRONMENT The healthcare industry is subject to numerous laws and regulations of federal, state and local governments. These laws and regulations include, but are not limited to, matters such as licensure, accreditation, government healthcare program participation requirement, reimbursement for patient services and Medicare and Medicaid fraud and abuse. Government activity has increased with respect to investigations and allegations concerning possible violations of fraud and abuse statutes and regulations by healthcare providers. Violations of these laws and regulations could result in expulsion from government healthcare programs together with the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed. Management believes that the Company is in compliance with fraud and abuse regulations, as well as other applicable government laws and regulations. While no material regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation, as well as regulatory actions unknown or unasserted at this time.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2022
INCOME TAXES [Abstract]
INCOME TAXES	9. INCOME TAXES Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. The Company’s net deferred tax assets relate primarily to its net operating loss carryforwards, allowance for doubtful accounts and stock-based compensation, partially offset by property and equipment and intangible assets. The Company has recorded a full valuation allowance to offset the net deferred tax assets, as it is more likely than not that the Company will not realize future benefits associated with these net deferred tax assets at December 31, 2022 and 2021. At December 31, 2022 and 2021, the Company had net deferred tax assets of $18.6 million and $15.2 million, respectively, against which a full valuation allowance has been recorded. The increase in the valuation allowance for the years ended December 31, 2022 and 2021 is $3.4 million and $1.7 million, respectively, resulting from additional net operating losses generated in the year. The deferred tax liabilities associated with the book versus tax basis difference of intangible assets are the result of an asset step-up pursuant to a June 2017 merger transaction (the “Merger”). Significant components of the Company’s net deferred tax assets at December 31, 2022 and 2021 are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Dollars in Thousands ​ 2022 2021 Deferred tax assets: ​ ​ Net operating loss and credit carryforwards ​ $ 18,410 ​ $ 17,604 Allowance for doubtful accounts ​ ​ 371 ​ ​ 403 Stock-based compensation ​ 1,906 ​ 915 Other ​ 140 ​ 127 Gross deferred tax assets ​ 20,827 ​ 19,049 Deferred tax liabilities: ​ ​ Property and equipment ​ (274) ​ (257) Intangible assets ​ (1,950) ​ (3,589) Other ​ (35) ​ (18) Gross deferred tax liabilities ​ (2,259) ​ (3,864) Net deferred tax assets ​ 18,568 ​ 15,185 Less valuation allowance ​ (18,568) ​ (15,185) Net deferred liability ​ $ — ​ $ — ​ The Company’s provision for income taxes for the years ended December 31, 2022 and December 31, 2021 relates to income taxes in states and other jurisdictions and differs from the amounts determined by applying the statutory federal income tax rate to the loss before income taxes for the following reasons: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Dollars in Thousands ​ ​ 2022 ​ 2021 Benefit at federal rate ​ $ (2,563) ​ $ (1,788) Increase (decrease) resulting from: ​ ​ State income taxes—net of federal benefit ​ (747) ​ (289) Miscellaneous permanent differences ​ 51 ​ 62 Warrant liability revaluation ​ (153) ​ (97) Meals and entertainment ​ ​ 32 ​ ​ 19 PPP Loan forgiven ​ ​ — ​ ​ (192) Income taxed to owners on Non-Controlling Interest (NCI) ​ ​ (3) ​ ​ (3) Change in valuation allowance ​ 3,383 ​ 2,288 Total income tax benefit ​ $ — ​ $ — ​ The income tax expense consists of the following for the years ended December 31, 2022 and 2021. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Dollars in Thousands ​ 2022 2021 Federal: ​ ​ Current ​ $ — ​ $ — Deferred ​ — ​ — Total Federal ​ $ — ​ $ — State: ​ ​ Current ​ $ — ​ $ — Deferred ​ — ​ — Total State ​ $ — ​ $ — Foreign: ​ ​ Current ​ $ — ​ $ — Deferred ​ — ​ — Total Foreign ​ $ — ​ $ — Total Tax Provision ​ $ — ​ $ — ​ The Company had available gross federal net operating loss (“NOL”) carryforwards of approximately $74 million, and state NOL carryforwards of $2.4 million as of December 31, 2022. Approximately $28 million of the federal NOLs will expire at various dates beginning in 2036 through 2037 if not utilized, while the remaining amount will have an indefinite life. Beginning in 2018, under the TCJ Act, federal loss carryforwards have an unlimited carryforward period, however such losses can only offset 80% of taxable income in any one year. Included in the total NOLs for 2022 are $47 million of federal losses that fall under these new rules. State NOLs expire on various dates. Section 382 of the Internal Revenue Code, and similar state regulations, contain provisions that may limit the NOL carryforwards available to be used to offset income in any given year upon the occurrence of certain events, including changes in the ownership interests of significant stockholders. In the event of a cumulative change in ownership in excess of 50% over a three-year period, the amount of the NOL carryforwards that the Company may utilize in any one year may be limited. The Company reduced its tax attributes (NOLs and tax credits) and generated a limitation on utilization of such attributes resulting from the Merger. At December 31, 2022, and as a result of the limitations under Section 382 of the Internal Revenue Code, the Company had a total of unused federal tax net operating loss carryforwards with expiration dates as follows: ​ ​ ​ ​ ​ ​ ​ Dollars in ​ ​ Thousands ​ 2022 2036 ​ $ 14,277 2037 ​ ​ 13,641 Unlimited life ​ 46,546 Total Federal ​ $ 74,464 ​ The Company has adopted guidance on accounting for uncertainty in income taxes which clarified the accounting for income taxes by prescribing the minimum threshold a tax position is required to meet before being recognized in the financial statements as well as guidance on de-recognition, measurement, classification and disclosure of tax positions. There are no material uncertain tax positions that would require recognition in the financial statements. The Company is obligated to file income tax returns in the U.S. federal jurisdiction and various U.S. states. Since the Company had losses in the past, all prior years that generated NOLs are open and subject to audit examination in relation to the NOL generated from those years. During the year ended December 31, 2022, the IRS completed an exam of the Company’s 2019 tax year, which resulted in a change to the NOL carryforward. Our evaluation of uncertain tax positions was performed for the tax years open to examination.

STOCKHOLDERS' EQUITY

STOCKHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2022
STOCKHOLDERS' EQUITY [Abstract]
STOCKHOLDERS' EQUITY	10. STOCKHOLDERS’ EQUITY Common Stock Pursuant to our Third Amended and Restated Certificate of Incorporation, as amended, we currently have 150,000,000 shares of common stock authorized for issuance. On December 20, 2018, the Company’s shareholders approved the proposal to authorize the Company’s Board of Directors to, in its discretion, amend the Company’s Third Amended and Restated Certificate of Incorporation to increase the total number of authorized shares of common stock from 150,000,000 shares to 250,000,000 shares. The Company has not yet implemented this increase. During the years ended December 31, 2022 and 2021, the Company issued 26,795 and 74,000 shares of its common stock, respectively, in connection with the exercise of 26,795 and 74,000 warrants, respectively. The warrant exercises resulted in net cash proceeds to the Company of less than $0.1 million and $0.4 million during the years ended December 31, 2022 and 2021, respectively. During the year ended December 31, 2021, the Company issued 55,147 shares of its common stock in connection with consulting services of approximately $0.2 million. During the year ended December 31 2021, the Company issued 1,379 shares of its common stock in connection with the exercise of 1,379 stock options. The stock option exercises resulted in net cash proceeds to the Company of $3,000 for the year ended December 31, 2021. LP 2020 Purchase Agreement ​ On March 26, 2020, the Company entered into a purchase agreement (the “LP 2020 Purchase Agreement”) with Lincoln Park pursuant to which Lincoln Park agreed to purchase from us, from time to time, up to $10,000,000 of our common stock, subject to certain limitations, during the 24 month term of the LP 2020 Purchase Agreement. ​ During the year ended December 31, 2021, we received approximately $1.3 million from the sale of 500,000 shares of common stock to Lincoln Park under the LP 2020 Purchase Agreement. The Company terminated the LP 2020 Purchase Agreement effective June 14, 2021. ​ At The Market Offering Agreement ​ On April 2, 2021, the Company entered into a sales agreement with A.G.P./Alliance Global Partners (“AGP”), pursuant to which the Company may offer and sell its common stock, par value $0.01 per share (the “Common Stock”) (the “Shares”), having aggregate sales proceeds of up to $22.0 million. Shares can be sold either directly to or through AGP as a sales agent (the “AGP Sales Agreement”), from time to time, in an “at the market offering” (as defined in Rule 415(a)(4) under the Securities Act of 1933, as amended) of the Shares (the “ATM Offering”). The Company is limited in the number of shares it can sell in the ATM Offering due to the offering limitations currently applicable to the Company under General Instruction I.B.6. of Form S-3 and the Company’s public float as of the applicable date of such sales, as well as the number of authorized and unissued shares available for issuance, in accordance with the terms of the AGP Sales Agreement. ​ The sale of our shares of Common Stock to or through AGP, will be made pursuant to the registration statement (the “Registration Statement”) on Form S-3 (File No. 333-237445), which was declared effective by the Securities and Exchange Commission (the “SEC”) on April 13, 2020, for an aggregate offering price of up to $50.0 million. Under the AGP Sales Agreement, Shares may be sold by any method permitted by law deemed to be an “at the market offering.” AGP will also be able to sell shares of Common Stock by any other method permitted by law, including in negotiated transactions with the Company’s prior written consent. Upon delivery of a placement notice and subject to the terms and conditions of the AGP Sales Agreement, AGP is required to use its commercially reasonable efforts consistent with its normal trading and sales practices, applicable state and federal law, rules and regulations, and the rules of The Nasdaq Capital Market to sell the Shares from time to time based upon the Company’s instructions, including any price, time or size limits specified by the Company. AGP is not under any obligation to purchase any of the Shares on a principal basis pursuant to the AGP Sales Agreement, except as otherwise agreed by AGP and the Company in writing and expressly set forth in a placement notice. AGP’s obligations to sell the Shares under the AGP Sales Agreement are subject to satisfaction of certain conditions, including customary closing conditions. The Company is not obligated to make any sales of Shares under the AGP Sales Agreement and any determination by the Company to do so will be dependent, among other things, on market conditions and the Company’s capital raising needs. The Company has agreed to pay AGP a cash fee of 3.0% of the aggregate gross proceeds from the sale of the Shares on the Company’s behalf pursuant to the AGP Sales Agreement. The AGP Sales Agreement contains representations, warranties and covenants that are customary for transactions of this type. In addition, the Company has provided AGP with customary indemnification and contribution rights. The Company has also agreed to reimburse AGP for certain specified expenses, including the expenses of counsel to AGP. The offering of the Shares pursuant to the AGP Sales Agreement will terminate upon the termination of the AGP Sales Agreement by AGP or the Company, as permitted therein. ​ During the years ended December 31, 2022 and 2021, we received net proceeds of approximately $0.1 million and $14.9 million, respectively, from the sale of 85,023 and 4,501,000 shares of common stock through AGP, respectively. ​ As of the date of issuance of this Annual Report on Form 10-K, we have received an aggregate of $15.5 million in net proceeds, after issuance costs of approximately $0.5 million, from the sale of 5,119,656 shares of common stock through AGP, including approximately $0.4 million in net proceeds from the sale of 533,633 shares of common stock through AGP from January 1, 2023 through the date of issuance of this Annual Report on Form 10-K. ​ Preferred Stock The Company’s Board of Directors is authorized to issue up to 15,000,000 shares of preferred stock in one or more series, from time to time, with such designations, powers, preferences and rights and such qualifications, limitations and restrictions as may be provided in a resolution or resolutions adopted by the Board of Directors. The authority of the Board of Directors includes, but is not limited to, the determination or fixing of the following with respect to shares of such class or any series thereof: (i) the number of shares; (ii) the dividend rate, whether dividends shall be cumulative and, if so, from which date; (iii) whether shares are to be redeemable and, if so, the terms and amount of any sinking fund providing for the purchase or redemption of such shares; (iv) whether shares shall be convertible and, if so, the terms and provisions thereof; (v) what restrictions are to apply, if any, on the issue or reissue of any additional preferred stock; and (vi) whether shares have voting rights. The preferred stock may be issued with a preference over the common stock as to the payment of dividends. We have no current plans to issue any additional preferred stock. Classes of stock such as the preferred stock may be used, in certain circumstances, to create voting impediments on extraordinary corporate transactions or to frustrate persons seeking to effect a merger or otherwise to gain control of the Company. For the foregoing reasons, any additional preferred stock issued by the Company could have an adverse effect on the rights of the holders of the common stock. Series B Preferred Stock The Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock (“Series B Preferred Stock”) with the State of Delaware, which designates 6,900 shares of our preferred stock as Series B Preferred Stock. The Series B Preferred Stock has a stated value of $1,000 per share and a par value of $0.01 per share. The Series B Preferred Stock includes a beneficial ownership blocker but has no dividend rights (except to the extent dividends are also paid on the common stock). On August 28, 2017, the Company completed an underwritten public offering (the “August 2017 Offering”) consisting of the Company’s Series B Preferred Stock and warrants. The conversion price of the Series B Preferred Stock contains a down round feature. The Company will recognize the effect of the down round feature when it is triggered. At that time, the effect would be treated as a deemed dividend and as a reduction of income available to common shareholders in our basic earnings per share calculation. There were no conversions of Series B Preferred Stock during the years ended December 31, 2022 and 2021, respectively. At December 31, 2022 and 2021, the Company had 6,900 shares of Series B designated and issued and 47 shares of Series B outstanding. Based on the stated value of $1,000 per share and a conversion price of $0.40 per share, the outstanding shares of Series B Preferred Stock at December 31, 2022 were convertible into 117,500 shares of common stock. Liquidation Preferences The following is the liquidation preferences for the Company’s preferred stock; Upon any liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary, the holders shall be entitled to receive out of the assets of the Corporation an amount equal to the par value, plus any accrued and unpaid dividends thereon, for each share of Preferred Stock before any distribution or payment shall be made to the holders of the Common Stock, and if the assets of the Corporation shall be insufficient to pay in full such amounts, then the entire assets to be distributed to the holders shall be ratably distributed among the holders in accordance with the respective amounts that would be payable on such shares. If all amounts were paid in full; and thereafter, the holders shall be entitled to receive out of the assets, whether capital or surplus, of the Corporation the same amount that a holder of Common Stock would receive if the Preferred Stock were fully converted to Common Stock which amount shall be paid pari passu with all holders of Common Stock. Common Stock Warrants The following represents a summary of the warrants outstanding as of December 31, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Underlying Exercise ​ ​ Issue Year ​ Expiration ​ Shares ​ Price Warrants ​ ​ ​ ​ ​ ​ ​ ​ ​ (1) ​ 2018 ​ April 2023 ​ 148,378 ​ $ 5.40 (2) ​ 2018 ​ July 2023 ​ 29,343 ​ $ 5.40 (3) ​ 2018 ​ August 2023 ​ 41,806 ​ $ 5.40 (4) ​ 2018 ​ September 2023 ​ 40,719 ​ $ 5.40 (5) ​ 2018 ​ November 2023 ​ 75,788 ​ $ 5.40 (6) ​ 2018 ​ December 2023 ​ 51,282 ​ $ 5.40 (7) ​ 2019 ​ April 2024 ​ 147,472 ​ $ 5.40 (8) ​ 2019 ​ May 2024 ​ 154,343 ​ $ 9.56 ​ 689,131 ​ (1) - (7) (8) ​ During the years ended December 31, 2022 and 2021, 115,975 and 239 warrants expired. These warrants had been issued in connection with transactions which were completed between 2016 and 2018. During the year ended December 31, 2021, 357 warrants were settled for cash of approximately $0.1 million. For further discussion, see the 2016 Warrant Liability in Note 11 – Fair Value. During the years ended December 31, 2022 and 2021, t here were 26,795 and 74,000 warrants exercised, respectively, for proceeds to the Company of approximately $11,000 and $0.4 million, respectively. the intrinsic value of the warrants exercised was less than $0.1 million and $0.1 million, respectively. Deemed Dividends Certain of our preferred stock and warrant issuances contain down round provisions which require us to recognize the effect of the down round feature when it is triggered. That effect is treated as a dividend and as a reduction of income available to common shareholders in basic earnings per share. Some warrants that expired or were exercised during the years ended December 31, 2022 and 2021 contained down round provisions but such provisions had no impact on the respective expiration or exercise dates. There were no deemed dividends recorded during the years ended December 31, 2022 and 2021.

FAIR VALUE

FAIR VALUE	12 Months Ended
	Dec. 31, 2022
FAIR VALUE [Abstract]
FAIR VALUE	11. FAIR VALUE FASB guidance on fair value measurements, which defines fair value, establishes a framework for measuring fair value and expands disclosures about fair value measurements for our financial assets and liabilities, as well as for other assets and liabilities that are carried at fair value on a recurring basis in our consolidated financial statements. FASB guidance establishes a three-level fair value hierarchy based upon the assumptions (inputs) used to price assets or liabilities. The three levels of inputs used to measure fair value are as follows: Level 1—Unadjusted quoted prices in active markets for identical assets or liabilities; Level 2—Observable inputs other than those included in Level 1, such as quoted prices for similar assets and liabilities in active markets or quoted prices for identical assets or liabilities in inactive markets; and Level 3—Unobservable inputs reflecting our own assumptions and best estimate of what inputs market participants would use in pricing the asset or liability. Common Stock Warrant Liabilities. Certain of our issued and outstanding warrants to purchase shares of common stock do not qualify to be treated as equity and, accordingly, are recorded as a liability. We are required to record these instruments at fair value at each reporting date and changes are recorded as a non-cash adjustment to earnings. The gains or losses included in earnings are reported in other income (expense) in our consolidated statement of operations. 2016 Warrant Liability The Company has a warrant liability related to warrants issued in January 2016 (the “2016 Warrant Liability”) and it represents the fair value of such warrants, of which, 357 warrants were settled for cash of approximately $0.1 million in January 2021. The balance of the 2016 Warrant Liability was zero as of December 31, 2021. Bridge Note Warrant Liabilities During 2019 and 2018, the Company issued warrants in connection with the issuance of convertible notes. All of these warrants issuances were classified as warrant liabilities (the “Bridge Note Warrant Liabilities”). The Bridge Note Warrant Liabilities are considered Level 3 financial instruments and were valued using the Black Scholes model. As of December 31, 2022, assumptions used in the valuation of the Bridge Note Warrant Liabilities include: remaining life to maturity of 0.3 to 1.41 years; annual volatility of 69% to 77%; and risk free rate of 4.42 to 4.76%. As of December 31, 2021, assumptions used in the valuation of the Bridge Note Warrant Liabilities include: remaining life to maturity of 0.3 to 2.4 years; annual volatility of 61% to 199%; and risk free rate of 0.06% to 0.73%. During the year ended December 31, 2021, the Company wrote-off $0.3 million of the Bridge Note Warrant Liability in connection with the exercise of 74,000 warrants. During the years ended December 31, 2022 and 2021, the change in the fair value of the warrant liabilities measured using significant unobservable inputs (Level 3) were comprised of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Dollars in Thousands ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, 2022 ​ ​ ​ ​ ​ ​ ​ Bridge Note ​ ​ ​ ​ Warrant Liabilities Beginning balance at January 1 ​ ​ ​ ​ ​ ​ ​ $ 606 Total losses: ​ ​ ​ ​ ​ ​ ​ Revaluation recognized in earnings ​ ​ ​ ​ ​ ​ ​ ​ (606) Balance at December 31 ​ ​ ​ ​ ​ ​ ​ $ – ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, 2021 ​ ​ 2016 Warrant ​ Bridge Note ​ Total Warrant ​ Liability Warrant Liabilities Liabilities Beginning balance at January 1 ​ $ 130 ​ $ 1,195 ​ $ 1,325 Total losses: ​ ​ ​ Revaluation recognized in earnings ​ ​ – ​ ​ (269) ​ ​ (269) Deductions – warrant exercises and write-offs ​ ​ – ​ ​ (320) ​ ​ (320) Deductions – warrant liability settlement ​ ​ (130) ​ ​ – ​ ​ (130) Balance at December 31 ​ $ – ​ $ 606 ​ $ 606 ​ ​

EQUITY INCENTIVE PLAN

EQUITY INCENTIVE PLAN	12 Months Ended
	Dec. 31, 2022
EQUITY INCENTIVE PLAN [Abstract]
EQUITY INCENTIVE PLAN	12. EQUITY INCENTIVE PLAN The Company currently issues stock awards under its 2017 Stock Option and Incentive Plan, as amended (the "2017 Plan") which will expire on June 5, 2027. The shares authorized for issuance under the 2017 Plan were 3,852,853 at December 31, 2022 of which 170,218 were available for future grant. The shares authorized under the 2017 Plan are subject to annual increases on January 1 by 5% of the number of shares of common stock issued and outstanding on the immediately preceding December 31, or such lessor number of shares determined by the Company’s Board of Directors or Compensation Committee. During the year ended December 31, 2022, the shares authorized for issuance increased by 1,135,422 shares. The Plan is administered by the Compensation Committee of the Board of Directors (the “Committee”), which has the authority to set the number, exercise price, term and vesting provisions of the awards granted under the Plan, subject to the terms thereof. Either incentive or non-qualified stock options may be granted to employees of the Company, but only non-qualified stock options may be granted to non-employee directors and advisors. However, in either case, the Plan requires that stock options must be granted at exercise prices not less than the fair market value of the common stock on the date of the grant. Options issued under the plan vest over periods as determined by the Committee and expire 10 years after the date the option was granted. Stock Options. The Company accounts for all stock-based compensation payments to employees and directors, including grants of employee stock options, at fair value at the date of grant and expenses the benefit in operating expense in the consolidated statements of operations over the service period of the awards. The Company records the expense for stock-based compensation awards subject to performance-based milestone vesting over the remaining service period when management determines that achievement of the milestone is probable based on the expected satisfaction of the performance conditions as of the reporting date. The fair value of each stock option granted is estimated on the date of grant using the Black-Scholes option pricing model, which requires various assumptions including estimating stock price volatility, expected life of the stock option, risk free interest rate and estimated forfeiture rate. During the year ended December 31, 2022, the Company granted stock options to purchase up to 1,114,000 shares of common stock at a weighted average exercise price of $1.51. These awards have vesting periods of up to four years and had a weighted average grant date fair value of $1.45. The fair value calculation of options granted during 2022 used the follow assumptions: risk free interest rates of 1.60% to 3.55%, based on the U.S. Treasury yield in effect at the time of grant; expected life of six years; and volatility of 166% to 167% based on historical volatility of the Company’s common stock over a time that is consistent with the expected life of the option. The following table summarizes stock option activity under our plans during the year ended December 31, 2022: ​ ​ ​ ​ ​ ​ ​ Number of Weighted-Average ​ ​ Options ​ Exercise Price Outstanding at January 1, 2022 2,635,287 ​ $ 3.38 Granted 1,114,000 ​ 1.51 Forfeited (67,951) ​ 2.18 Outstanding at December 31, 2022 3,681,336 ​ $ 2.84 Exercisable at December 31, 2022 2,167,604 ​ $ 3.24 ​ As of December 31, 2022, there were 3,295,639 options that were vested or expected to vest with an aggregate intrinsic value of zero and a remaining weighted average contractual life of 8.2 years. During the year ended December 31, 2021, there were 1,907,347 options granted with a weighted average exercise price of $2.89, 1,379 options exercised with a weighted average exercise price of $2.06 and 93,673 options forfeited with a weighted average exercise price of $2.82. During the years ended December 31, 2022 and 2021, we recorded compensation expense for all stock awards of $3.8 million and $1.9 million, respectively, within operating expense in the accompanying statements of operations. As of December 31, 2022, the unrecognized compensation expense related to unvested stock awards was $3.1 million, which is expected to be recognized over a weighted-average period of 2.6 years.

SALES SERVICE REVENUE, NET AND

SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE	12 Months Ended
	Dec. 31, 2022
SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE [Abstract]
SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE	13 SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE ASC Topic 606, “Revenue from contracts with customers” ​ The Company follows the guidance of ASC 606 for the recognition of revenue from contracts with customers to transfer goods and services. The Company performed a comprehensive review of its existing revenue arrangements following the five-step model: ​ Step 1: Identification of the contract with the customer. Sub-steps include determining the customer in a contract, initial contract identification and determining if multiple contracts should be combined and accounted for as a single transaction. Step 2: Identify the performance obligation in the contract. Sub-steps include identifying the promised goods and services in the contract and identifying which performance obligations within the contract are distinct. Step 3: Determine the transaction price. Sub-steps include variable consideration, constraining estimates of variable consideration, the existence of a significant financing component in the contract, noncash consideration and consideration payable to a customer. Step 4: Allocate transaction price. Sub-steps include assessing the amount of consideration to which the Company expects to be entitled in exchange for transferring the promised goods or services to the customer. Step 5: Satisfaction of performance obligations. Sub-steps include ascertaining the point in time when an asset is transferred to the customer and when the customer obtains control of the asset upon which time the Company recognizes revenue. ​ Nature of Contracts and Customers The Company’s contracts and related performance obligations are similar for its customers and the sales process for all customers starts upon the receipt of requisition forms from the customers for patient diagnostic testing and the execution of contracts for biomarker testing and clinical research. Payment terms for the services provided are 30 days, unless separately negotiated. ​ Diagnostic testing ​ Control of the laboratory testing services is transferred to the customer at a point in time. As such, the Company recognizes revenue for laboratory testing services at a point in time based on the delivery method (web-portal access or fax) for the patient’s laboratory report, per the contract. ​ Clinical research grants ​ Control of the clinical research services are transferred to the customer over time. The Company will recognize revenue utilizing the “effort based” method, measuring its progress toward complete satisfaction of the performance obligation. ​ Biomarker testing and clinical project services ​ Control of the biomarker testing and clinical project services are transferred to the customer over time. The Company utilizes an “effort based” method of assessing performance and measures progress towards satisfaction of the performance obligation based upon the delivery of results. ​ The Company generates revenue from the provision of diagnostic testing provided to patients, biomarker testing provided to bio-pharma customers and clinical research grants funded by both bio-pharma customers and government health programs. ​ Reagents and other diagnostic products Control of reagents and other diagnostic products are transferred to the customer at a point in time and, as such, the Company recognizes these revenues at a point in time based on the delivery method. These revenues include revenues from reagent sets for our HSRR program, COVID-19 antibody tests and other product sales and are included in other revenue in our consolidated statements of operations. ​ Equipment leasing The Company accounts for sales-type leases within the scope of ASC 842, Leases, as ASC 606 specifically excludes leases from its guidance. The sales-type leases result in the derecognition of the underlying asset, the recognition of profit or loss on the sale, and the recognition of an investment in leased asset. ​ Disaggregation of Revenues by Transaction Type ​ We operate in one business segment and, therefore, the results of our operations are reported on a consolidated basis for purposes of segment reporting, consistent with internal management reporting. Service revenue, net for the years ended December 31, 2022 and 2021 was as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, (dollars in thousands) ​ Diagnostic Testing ​ Biomarker Testing ​ Total ​ 2022 2021 2022 2021 2022 2021 Medicaid ​ $ 50 ​ $ 43 ​ $ — ​ $ — ​ $ 50 ​ $ 43 Medicare ​ 3,831 ​ 3,838 ​ — ​ — ​ 3,831 ​ 3,838 Self-pay ​ 326 ​ 234 ​ — ​ — ​ 326 ​ 234 Third party payers ​ 4,211 ​ 3,612 ​ — ​ — ​ 4,211 ​ 3,612 Contract diagnostics ​ — ​ — ​ — ​ 56 ​ — ​ 56 Service revenue, net ​ $ 8,418 ​ $ 7,727 ​ $ — ​ $ 56 ​ $ 8,418 ​ $ 7,783 ​ Revenue from the Medicare and Medicaid programs account for a portion of the Company’s patient diagnostic service revenue. Laws and regulations governing those programs are extremely complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term. ​ Revenue Recognition ​ Revenue is recognized when a customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To the extent the transaction price includes variable consideration, the Company estimates the amount of variable consideration that should be included in the transaction price using the expected value method based on historical experience. The Company does not typically enter arrangements where multiple contracts can be combined as the terms regarding services are generally found within a single agreement/requisition form. The Company derives its revenues from the following types of transactions: diagnostic testing (“Diagnostic”), revenues from the Company’s ICP technology and bio-pharma projects encompassing genetic diagnostics (collectively “Biomarker”), revenues from clinical research grants from state and federal research programs and diagnostic product sales, including revenues from equipment leases and reagent sales associated with our HSRR program ​ Deferred revenue ​ ​ Contractual Allowances and Adjustments We are reimbursed by payers for services we provide. Payments for services covered by payers average less than billed charges. We monitor revenue and receivables from payers and record an estimated contractual allowance for certain revenue and receivable balances as of the revenue recognition date to properly account for anticipated differences between amounts estimated in our billing system and amounts ultimately reimbursed by payers. Accordingly, the total revenue and receivables reported in our consolidated financial statements are recorded at the amounts expected to be received from these payers. For service revenue, the contractual allowance is estimated based on several criteria, including unbilled claims, historical trends based on actual claims paid, current contract and reimbursement terms and changes in customer base and payer/product mix. The billing functions for the remaining portion of our revenue are contracted and fixed fees for specific services and are recorded without an allowance for contractual discounts. The following table presents our revenues initially recognized for each associated payer class during the years ended December 31, 2022 and 2021. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, (dollars in thousands) ​ ​ ​ Contractual Allowances and ​ Revenues, net of Contractual ​ ​ Gross Revenues ​ adjustments ​ Allowances and adjustments ​ 2022 2021 2022 2021 2022 2021 Medicaid ​ $ 50 ​ $ 43 ​ $ — ​ $ — ​ $ 50 ​ $ 43 Medicare ​ 3,831 ​ 3,838 ​ — ​ — ​ 3,831 ​ 3,838 Self-pay ​ 326 ​ 234 ​ — ​ — ​ 326 ​ 234 Third party payers ​ 14,681 ​ 12,597 ​ (10,470) ​ (8,985) ​ 4,211 ​ 3,612 Contract diagnostics ​ – ​ 56 ​ — ​ — ​ — ​ 56 ​ ​ 18,888 ​ 16,768 ​ (10,470) ​ (8,985) ​ 8,418 ​ 7,783 Other ​ 1,402 ​ 914 ​ — ​ — ​ 1,402 ​ 914 ​ ​ $ 20,290 ​ $ 17,682 ​ $ (10,470) ​ $ (8,985) ​ $ 9,820 ​ $ 8,697 ​ Allowance for Doubtful Accounts ​ The Company provides for a general allowance for collectability of services when recording net sales. The Company has adopted the policy of recognizing net sales to the extent it expects to collect that amount. Reference FASB 954-605-45-5 and ASU 2011-07, Health Care Entities: Presentation and Disclosure of Patient Service Revenue, Provision for Bad Debt, and the Allowance for Doubtful Accounts. The change in the allowance for doubtful accounts is directly related to the increase in patient service revenues. The following table presents our reported revenues net of the collection allowance and adjustments for the years ended December 31, 2022 and 2021. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ Revenues, net of ​ ​ ​ (dollars in thousands) ​ Contractual Allowances ​ Allowances for doubtful ​ ​ ​ and adjustments ​ accounts ​ Total ​ 2022 2021 2022 2021 2022 2021 Medicaid ​ $ 50 ​ $ 43 ​ $ (25) ​ $ (5) ​ $ 25 ​ $ 38 Medicare ​ 3,831 ​ 3,838 ​ (110) ​ (58) ​ 3,721 ​ 3,780 Self-pay ​ 326 ​ 234 ​ (19) ​ — ​ 307 ​ 234 Third party payers ​ 4,211 ​ 3,612 ​ (254) ​ 215 ​ 3,957 ​ 3,827 Contract diagnostics ​ — ​ 56 ​ — ​ — ​ — ​ 56 ​ ​ 8,418 ​ 7,783 ​ (408) ​ 152 ​ 8,010 ​ 7,935 Other ​ 1,402 ​ 914 ​ — ​ — ​ 1,402 ​ 914 ​ ​ $ 9,820 ​ $ 8,697 ​ $ (408) ​ $ 152 ​ $ 9,412 ​ $ 8,849 ​ Costs to Obtain or Fulfill a Customer Contract ​ Sales commissions are expensed when incurred because the amortization period would have been one year or less. These costs are recorded in operating expenses in the consolidated statements of operations. ​ Shipping and handling costs are comprised of inbound and outbound freight and associated labor. The Company accounts for shipping and handling activities related to contracts with customers as fulfillment costs which are included in cost of sales in the consolidated statements of operations. ​ Accounts Receivable The Company has provided an allowance for potential credit losses, which has been determined based on management’s industry experience. The Company grants credit without collateral to its patients, most of who are insured under third party payer agreements. The following summarizes the mix of receivables as of December 31, 2022 and 2021: ​ ​ ​ ​ ​ ​ ​ (dollars in thousands) December 31, 2022 December 31, 2021 Medicaid ​ $ 34 ​ $ 45 Medicare ​ 1,124 ​ 727 Self-pay ​ 291 ​ 139 Third party payers ​ 1,888 ​ 2,111 Contract diagnostic services and other ​ 53 ​ 159 ​ ​ $ 3,390 ​ $ 3,181 Less allowance for doubtful accounts ​ (2,354) ​ (2,484) Accounts receivable, net ​ $ 1,036 ​ $ 697 ​ The following table presents the roll-forward of the allowance for doubtful accounts for the year ended December 31, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Allowance for ​ ​ ​ ​ ​ Doubtful (dollars in thousands) ​ ​ ​ ​ Accounts Balance, January 1, 2022 ​ ​ $ (2,484) Collection Allowance: ​ ​ Medicaid ​ $ (25) ​ Medicare ​ (110) ​ Self-pay ​ ​ (19) ​ ​ ​ Third party payers ​ (254) ​ ​ ​ (408) ​ Bad debt expense ​ $ 2 ​ Total charges ​ ​ (406) Other ​ ​ ​ ​ ​ 536 Balance, December 31, 2022 ​ ​ $ (2,354) ​ Customer Revenue and Accounts Receivable Concentration Customer revenue and accounts receivable concentration amounted to the following for the identified periods. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net sales ​ ​ Accounts receivable, as of ​ ​ ​ Years Ended ​ ​ ​ ​ ​ ​ December 31, ​ ​ December 31, ​ December 31, ​ ​ ​ 2022 ​ 2021 ​ ​ 2022 ​ 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Customer A ​ * ​ * ​ ​ * ​ 21 % Customer B ​ * ​ * ​ ​ * ​ 12 % Customer C ​ * ​ * ​ ​ 12 % * ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ * represents less than 10% ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	14. SUBSEQUENT EVENTS The Company has evaluated events and transactions subsequent to December 31, 2022 through the date the consolidated financial statements were issued. Outside of the items noted below, there are no other events to report other than what has been disclosed in the consolidated financial statements. ​ Factoring and Security Agreement ​ Effective March 27, 2023, we entered into a Factoring and Security Agreement (the “Factoring Agreement”) with Culain Capital Funding, LLC (“Culain”) for the purpose of factoring certain of our accounts receivable. Under the terms of the Factoring Agreement, we may offer for sale, and Culain may purchase in its sole discretion, certain accounts receivable of ours (the “Purchased Receivables”), which are payable directly by Culain, subject to certain repurchase obligations we have. The Factoring Agreement provides for a maximum of $2,000,000 in Purchased Receivables. Upon purchase of a Purchased Receivable, Culain will pay us 85% of the amount of the Purchased Receivable and the balance (less fees) is paid to us upon collection of the Purchased Account by Culain ​ Culain’s fee for each Purchased Receivable is based on an initial discount rate of one and twenty-five hundredths percent (1.25%) of the Gross Amount or Net Amount (as such term is defined in the Factoring Agreement) of a Purchased Receivable, as applicable, used to determine the initial payment with respect to such Purchased Receivable for a period of 30 days (the “Fixed Discount Period “) followed by variable fees calculated as a daily percentage rate equal to forty-two thousandths percent (0.042%), commencing on the first (1st) calendar day after the end of the Fixed Discount Period with respect to such Purchased Receivable and other miscellaneous fees. We may also be required to repurchase uncollectible Purchased Receivables or upon default for an amount equal to the then-unpaid face amount due on any such accounts. Our obligations under the Factoring Agreement are secured by a continuing security interest in all of our assets, properties, and rights, wherever located, whether owned as of the date of the Factoring Agreement or subsequent thereto including but not limited to our present and future accounts receivable and all chattel paper, instruments, general intangibles, securities, contract rights, insurance, proceeds, property rights and interests associated therewith, as well as all equipment, inventory and deposit accounts as more fully described in the Factoring Agreement, in order to secure our payment and performance obligations to Culain under the Factoring Agreement. ​ The Factoring Agreement has an initial term of 12 months and automatically renews for successive 12-month ​ The Factoring Agreement contains covenants that are customary for accounts receivable-based factoring agreements and also contains provisions relating to events of default that are customary for agreements of this type. ​ The foregoing summary of the Factoring Agreement is qualified in its entirety by reference to the Factoring Agreement, a copy of which is filed as Exhibit 10.15 to this Annual Report on Form 10-K for the year ended December 31, 2022. ​

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2022
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Principles of Consolidation	Principles of Consolidation. The consolidated financial statements include the accounts of Precipio, Inc. and our wholly owned subsidiaries, and the Joint Venture which is a VIE in which we are the primary beneficiary. Refer to the section titled “Consolidation of Variable Interest Entities” for further information related to our accounting for the Joint Venture. All inter-company balances and transactions have been eliminated in consolidation.
Use of Estimates	Use of Estimates. The preparation of the consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of net sales and expenses during the reporting period. The most significant estimates and assumptions with regard to these consolidated financial statements relate to the allowance for doubtful accounts, assumptions used within the fair value of debt and equity transactions and contractual allowances. These assumptions require considerable judgment by management. Actual results could differ from the estimates and assumptions used in preparing these consolidated financial statements.
Reclassifications	Reclassification. Certain reclassifications were made to the statements of cash flows related to splitting accruals and deferred revenue to separate lines in order to conform to the 2022 presentation. These reclassifications had no effect on previously reported retained earnings, net income, total assets or liabilities, or cash flows used in operating activities.
Risks and Uncertainties	Certain risks and uncertainties are inherent in our day-to-day operations and in the process of preparing our financial statements. The risks and uncertainties may be heightened by the COVID-19 pandemic and any worsening of the global business and economic environment as a result. The more significant of those risks are presented below and throughout the notes to the consolidated financial statements. The Company operates in the healthcare industry which is subject to numerous laws and regulations of federal, state and local governments. These laws and regulations include, but are not necessarily limited to, matters such as licensure, accreditation, government healthcare program participation requirements, reimbursement for patient services, and Medicare and Medicaid fraud and abuse. Government activity has increased with respect to investigations and allegations concerning possible violations of fraud and abuse statutes and regulations by healthcare providers. Violations of these laws and regulations could result in expulsion from government healthcare programs together with the imposition of significant fines and penalties, as well as significant repayments for patient services previously billed. Management believes that the Company is in compliance with fraud and abuse regulations, as well as other applicable government laws and regulations. While no material regulatory inquiries have been made, compliance with such laws and regulations can be subject to future government review and interpretation as well as regulatory actions unknown or unasserted at this time.
Fair Value	Fair Value. Unless otherwise specified, book value approximates fair value. The common stock warrant liabilities are recorded at fair value. See Note 11 - Fair Value for additional information.
Other Current Assets	Other Current Assets. Other current assets of $0.5 million as of December 31, 2022 include prepaid insurance of approximately $0.3 million and prepaid and other assets of $0.2 million. Other current assets of $0.5 million as of December 31, 2021 include prepaid insurance of $0.3 million and prepaid and other assets of $0.2 million.
Concentrations of Risk	Concentrations of Risk. From time to time, we may maintain a cash position with financial institutions in amounts that exceed Federal Deposit Insurance Corporation insured limits of up to $250,000 per depositor per financial institution. We have not experienced any losses on such accounts as of December 31, 2022. Service companies in the health care industry typically grant credit without collateral to patients. The majority of these patients are insured under third-party insurance agreements. The services provided by the Company are routinely billed utilizing the Current Procedural Terminology (CPT) code set designed to communicate uniform information about medical services and procedures among physicians, coders, patients, accreditation organizations, and payers for administrative, financial, and analytical purposes. CPT codes are currently identified by the Centers for Medicare and Medicaid Services and third-party payers. The Company utilizes CPT codes for Pathology and Laboratory Services contained within codes 80000-89398.
Inventories	Inventories. Inventories consist of laboratory supplies and are valued at cost (determined on an average cost basis, which approximates the first-in, first-out method) or net realizable value, whichever is lower. We evaluate inventory for items that are slow moving or obsolete and record an appropriate reserve for obsolescence if needed. We have an allowance for slow moving or obsolete inventory of zero and less than $0.1 million at December 31, 2022 and 2021, respectively.
Property and Equipment, net	Property and Equipment, net. Property and equipment are carried at cost, net of accumulated depreciation and amortization. Expenditures for maintenance and repairs are expensed as incurred. Depreciation and amortization are computed by the straight-line method over the estimated useful lives of the related assets as follows: ​ ​ ​ ​ Furniture and fixtures 5 to 7 years Laboratory equipment 3 to 10 years Computer equipment and software 3 to 7 years ​ For assets sold or otherwise disposed of, the cost and related accumulated depreciation and amortization are removed from the accounts, and any related gain or loss is reflected in operations for the period. Expenditures for major betterments that extend the useful lives of property and equipment are capitalized.
Intangible Assets.	Intangible Assets. We review our amortizable long-lived assets for impairment annually or whenever events indicate that the carrying amount of the asset (group) may not be recoverable. An impairment loss may be needed if the sum of the future undiscounted cash flows is less than the carrying amount of the asset (group). The amount of the loss would be determined by comparing the fair value of the asset to the carrying amount of the asset (group). There were no impairment charges on our amortizable long-lived assets during the years ended December 31, 2022 and 2021.
Debt Issuance Costs	Debt Issuance Costs Debt issuance costs are being amortized over the lives of the related financings on a basis that approximates the effective interest method. Costs are presented as a reduction of the related debt in the accompanying balance sheets. The amortization expense recorded was less than $0.1 million for the years ended December 31, 2022 and 2021, respectively. See Note 5 – Long Term Debt for further discussion.
Stock-Based Compensation	Stock-Based Compensation. All stock-based awards to date have exercise prices equal to the market price of our common stock on the date of grant and have ten-year contractual terms. Stock-based compensation cost is based on the fair value of the portion of stock-based awards that is ultimately expected to vest. The Company utilizes the Black-Scholes option pricing model for determining the estimated fair value for stock-based awards. Unvested awards as of December 31, 2022 had vesting periods of up to four years from the date of grant. No awards outstanding at December 31, 2022 and 2021, respectively, are subject to performance vesting conditions or market-based vesting.
Net Sales Recognition	Net Sales Recognition. Revenue recognition occurs when a customer obtains control of the promised goods and service. Revenue assigned to the goods and services reflects the consideration which the Company expects to receive in exchange for those goods and services. ​ The Company derives its revenues from diagnostic testing - histology, flow cytometry, cytology and molecular testing; clinical research from bio-pharma customers, state and federal grant programs; biomarker testing from bio-pharma customers and from other product sales including revenues from equipment leases and reagent sales associated with our HSRR program ​ The Company recognizes revenue utilizing the five-step framework of ASC 606. Control of the laboratory testing services is transferred to the customer at a point in time. As such, the Company recognizes revenue for diagnostic testing at a point in time based on the delivery method (web-portal access or fax) for a patient’s laboratory report. Diagnostic testing service revenue is reported at the estimated net realizable amounts from patients, third-party payers and others for services rendered, including retroactive adjustment under reimbursement agreements with third-party payers. Provisions for third-party payer settlements are provided in the period in which the related services are rendered and adjusted in the future periods, as final settlements are determined. For clinical research and biomarker services, the Company utilizes an “effort based” method of assessing performance and measures progress towards satisfaction of the performance obligation based upon the delivery of results per the contract. Control of reagents and other diagnostic products are transferred to the customer at a point in time and, as such, the Company recognizes these revenues at a point in time based on the delivery method. When we receive payment in advance, we initially defer the revenue and recognize it when we deliver the service. ​ Taxes collected from customers and remitted to government agencies for specific net sales producing transactions are recorded net with no effect on the statements of operations.
Accounts Receivable	Accounts Receivable Accounts Receivable result from diagnostic services provided to self-pay and insured patients, project based testing services and clinical research. The payment for services provided by the Company are generally due within 30 days from the invoice date. Accounts receivable are reduced by an allowance for doubtful accounts. In evaluating the collectability of accounts receivable, the Company analyzes and identifies trends for each of its sources of revenue to estimate the appropriate allowance for doubtful accounts. For receivables associated with self-pay patients, including patients with insurance and a deductible and copayment, the Company records an allowance for doubtful accounts in the period of services on the basis of past experience of patients unable or unwilling to pay for service fee for which they are financially responsible. For receivables associated with services provided to patients with third-party coverage, the Company analyzes contractually due amounts and provides an allowance, if necessary. The difference between the standard rates and the amounts actually collected after all reasonable collection efforts have been exhausted is charged against the allowance for doubtful accounts.
Presentation of Insurance Claims and Related Insurance Recoveries	Presentation of Insurance Claims and Related Insurance Recoveries. The Company accounts for its insurance claims and related insurance recoveries at their gross values as standards for health care entities do not allow the Company to net insurance recoveries against the related claim liabilities. There were no insurance claims or insurance recoveries recorded during the years ended December 31, 2022 and 2021.
Advertising Costs	Advertising Costs. Advertising costs are expensed as incurred and are included in operating expenses on the consolidated statements of operations. Advertising costs charged to operations totaled approximately $0.1 million in 2022 and 2021, respectively.
Research and Development Costs	Research and Development Costs. All costs associated with internal research and development are expensed as incurred. These costs include salaries and employee related expenses, operating supplies and facility-related expenses. Research and development costs charged to operations totaled $1.7 million and $1.3 million for the years ended December 31, 2022 and 2021, respectively.
Income Taxes	Income Taxes. Deferred tax assets and liabilities are determined based on the differences between the financial reporting and tax basis of assets and liabilities at each balance sheet date using tax rates expected to be in effect in the year the differences are expected to reverse. The effect on the deferred tax assets and liabilities of a change in tax rates is recognized in the period when the change in tax rates is enacted. A valuation allowance is established when it is determined that it is more likely than not that some portion or all of the deferred tax assets will not be realized. A full valuation allowance has been applied against the Company’s net deferred tax assets as of December 31, 2022 and 2021, due to projected losses and because it is not more likely than not that the Company will realize future benefits associated with these deferred tax assets. Management’s conclusions regarding uncertain tax positions may be subject to review and adjustment at a later date based upon ongoing analysis of, or changes in tax laws, regulations and interpretations thereof as well as other factors. The Company’s policy is to record interest and penalties directly related to income taxes as income tax expense in the accompanying consolidated statements of operations, of which there was none for the years ended December 31, 2022 and 2021.
Common Stock Warrants	Common Stock Warrants. The Company classifies the issuance of common stock warrants as equity any contracts that (i) require physical settlement or net-stock settlement or (ii) gives the Company a choice of net-cash settlement or settlement in its own stocks (physical settlement or net-stock settlement). The Company classifies as assets or liabilities any contracts that (i) require net-cash settlement (including a requirement to net-cash settle the contract if an event occurs and if that event is outside of the Company’s control), or (ii) gives the counterparty a choice of net-cash settlement or settlement in stock (physical settlement or net-stock settlement). Certain of our issued and outstanding warrants to purchase common stock do not qualify to be treated as equity and accordingly, are recorded as a liability (“Common Stock Warrant Liability”). We are required to present these instruments at fair value at each reporting date and any changes in fair values are recorded as an adjustment to earnings.
Consolidation of Variable Interest Entities	Consolidation of Variable Interest Entities. We evaluate any entity in which we are involved to determine if the entity is a VIE and if so, whether we hold a variable interest and are the primary beneficiary. We consolidate VIEs that are subject to assessment when we are deemed to be the primary beneficiary of the VIE. The process for determining whether we are the primary beneficiary of the VIE is to conclude whether we are a party to the VIE holding a variable interest that meets both of the following criteria: (1) has the power to make decisions that most significantly affect the economic performance of the VIE, and (2) has the obligation to absorb losses or the right to receive benefits that in either case could potentially be significant to the VIE. We have determined that we hold a variable interest in the Joint Venture, have the power to make significant operational decisions on behalf of the VIE and also have the obligation to absorb the majority of the losses from the VIE. As such we have also determined that we are the primary beneficiary of the VIE. The following table presents information about the carrying value of the assets and liabilities of the Joint Venture which we consolidate and which are included on our consolidated balance sheets. Intercompany balances are eliminated in consolidation and not reflected in the following table. ​ ​ ​ ​ ​ ​ ​ (dollars in thousands) December 31, 2022 December 31, 2021 Assets: ​ ​ ​ ​ ​ ​ Accounts receivable, net ​ $ 335 ​ $ 180 Total assets ​ $ 335 ​ $ 180 Liabilities: ​ ​ ​ ​ ​ ​ Accrued expenses ​ $ 50 ​ $ 36 Total liabilities ​ $ 50 ​ $ 36 Noncontrolling interest in Joint Venture ​ $ 65 ​ $ 40 Total stockholders' equity ​ $ 127 ​ $ 79 ​
Loss Per Share	Loss Per Share. Basic loss per share is calculated based on the weighted-average number of common shares outstanding during each period. Diluted loss per share includes shares issuable upon exercise of outstanding stock options, warrants or conversion rights that have exercise or conversion prices below the market value of our common stock. Options, warrants and conversion rights pertaining to 4,487,967 and 3,584,688 shares of our common stock have been excluded from the computation of diluted loss per share at December 31, 2022 and 2021, respectively, because the effect is anti-dilutive due to the net loss. The following table summarizes the outstanding securities not included in the computation of diluted net loss per share: ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Stock options 3,681,336 2,635,287 Warrants 689,131 831,901 Preferred stock 117,500 117,500 Total 4,487,967 3,584,688 ​
Recent Accounting Pronouncements	Recent Accounting Pronouncements Not Yet Adopted. In June 2022, the FASB issued ASU 2022-03, Fair Value Measurement (Topic 820) (“ASU 2022-03”). The amendments in ASU 2022-03 clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendments also clarify that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The amendments in this Update also require additional disclosures for equity securities subject to contractual sale restrictions. The provisions in this Update are effective for fiscal years beginning after December 15, 2023. Early adoption is permitted. The Company does not expect to early adopt this ASU. The Company is currently assessing the potential impact that the adoption of this ASU will have on its consolidated financial statements. In August 2020, the FASB issued ASU 2020-06 “ Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity In June 2016, the FASB issued ASU 2016-13 “ Measurement of Credit Losses on Financial Instruments ​

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2022
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES [Abstract]
Estimated Useful Lives of Property and Equipment	​ ​ ​ ​ Furniture and fixtures 5 to 7 years Laboratory equipment 3 to 10 years Computer equipment and software 3 to 7 years
Schedule of Variable Interest Entities	​ ​ ​ ​ ​ ​ ​ (dollars in thousands) December 31, 2022 December 31, 2021 Assets: ​ ​ ​ ​ ​ ​ Accounts receivable, net ​ $ 335 ​ $ 180 Total assets ​ $ 335 ​ $ 180 Liabilities: ​ ​ ​ ​ ​ ​ Accrued expenses ​ $ 50 ​ $ 36 Total liabilities ​ $ 50 ​ $ 36 Noncontrolling interest in Joint Venture ​ $ 65 ​ $ 40 Total stockholders' equity ​ $ 127 ​ $ 79
Outstanding Securities not Included in the Computation of Diluted Net Loss	The following table summarizes the outstanding securities not included in the computation of diluted net loss per share: ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2022 2021 Stock options 3,681,336 2,635,287 Warrants 689,131 831,901 Preferred stock 117,500 117,500 Total 4,487,967 3,584,688 ​

PROPERTY AND EQUIPMENT, NET (Ta

PROPERTY AND EQUIPMENT, NET (Tables)	12 Months Ended
	Dec. 31, 2022
PROPERTY AND EQUIPMENT, NET [Abstract]
Summary of Property and Equipment, Net	A summary of property and equipment at December 31, 2022 and 2021 is as follows: ​ ​ ​ ​ ​ ​ ​ ​ 2022 2021 Furniture and fixtures and leasehold improvements ​ $ 24 ​ $ 12 Laboratory equipment ​ 931 ​ 794 Computer equipment and laboratory software ​ 990 ​ 725 Construction in process ​ 34 ​ 138 ​ ​ 1,979 ​ 1,669 Less—accumulated depreciation and amortization ​ (1,102) ​ (833) Total ​ $ 877 ​ $ 836 ​

INTANGIBLES (Tables)

INTANGIBLES (Tables)	12 Months Ended
	Dec. 31, 2022
INTANGIBLES [Abstract]
Schedule of Intangible Assets	Intangible assets consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Dollars in Thousands ​ ​ December 31, 2022 ​ ​ ​ Accumulated Net Book ​ ​ Cost ​ Amortization ​ Value Technology ​ $ 18,990 ​ $ 5,222 ​ $ 13,768 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Dollars in Thousands ​ ​ December 31, 2021 ​ ​ ​ Accumulated Net Book ​ ​ Cost ​ Amortization ​ Value Technology ​ $ 18,990 ​ $ 4,273 ​ $ 14,717 ​
Intangible Assets, Estimated Useful Life	​

LONG-TERM DEBT (Tables)

LONG-TERM DEBT (Tables)	12 Months Ended
	Dec. 31, 2022
LONG-TERM DEBT [Abstract]
Schedule of debt	Long-term debt consists of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ Dollars in Thousands ​ December 31, 2022 December 31, 2021 Connecticut Department of Economic and Community Development (DECD) ​ $ 176 ​ $ 205 DECD debt issuance costs ​ (15) ​ (19) Financed insurance loan ​ 228 ​ — Total long-term debt ​ 389 ​ 186 Current portion of long-term debt ​ (255) ​ (26) Long-term debt, net of current maturities ​ $ 134 ​ $ 160 ​
Schedule of Maturities of Long-term Debt	The aggregate future maturities required on gross long-term debt at December 31, 2022 are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2023 2024 2025 2026 2027 2028 and thereafter Total DECD loan ​ $ 30 ​ $ 31 ​ $ 32 ​ $ 33 ​ $ 34 ​ $ 16 ​ $ 176 Financed insurance loan ​ ​ 228 ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ — ​ ​ 228 ​ ​ $ 258 ​ $ 31 ​ $ 32 ​ $ 33 ​ $ 34 ​ $ 16 ​ $ 404

ACCRUED EXPENSES OTHER CURREN_2

ACCRUED EXPENSES OTHER CURRENT LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2022
ACCRUED EXPENSES OTHER CURRENT LIABILITIES [Abstract]
Accrued expenses	Accrued expenses at December 31, 2022 and 2021 are as follows: ​ ​ ​ ​ ​ ​ ​ (dollars in thousands) 2022 2021 Accrued expenses ​ $ 983 ​ $ 1,033 Accrued compensation ​ 491 ​ 718 Accrued franchise, property and sales and use taxes ​ ​ 91 ​ ​ 148 Accrued interest ​ 19 ​ 19 ​ ​ $ 1,584 ​ $ 1,918 ​

LEASES (Tables)

LEASES (Tables)	12 Months Ended
	Dec. 31, 2022
LEASES [Abstract]
Summary of balance sheet presentation of our operating and finance leases	​ ​ ​ ​ ​ ​ ​ ​ (dollars in thousands) ​ ​ ​ ​ ​ ​ Classification on the Consolidated Balance Sheet ​ December 31, 2022 ​ December 31, 2021 Assets: ​ ​ ​ ​ ​ ​ Operating lease right-of-use assets, net ​ $ 763 ​ $ 858 Finance lease right-of-use assets, net (1) ​ ​ 257 ​ ​ 371 Total lease assets ​ $ 1,020 ​ $ 1,229 ​ ​ ​ ​ ​ ​ ​ Liabilities: ​ ​ ​ ​ ​ ​ Current: ​ ​ ​ ​ ​ ​ Current maturities of operating lease liabilities ​ $ 199 ​ $ 166 Current maturities of finance lease liabilities ​ ​ 162 ​ ​ 222 Noncurrent: ​ ​ ​ ​ ​ ​ Operating lease liabilities, less current maturities ​ ​ 574 ​ ​ 697 Finance lease liabilities, less current maturities ​ ​ 68 ​ ​ 159 Total lease liabilities ​ $ 1,003 ​ $ 1,244 ​ (1)
Summary of estimated future minimum lease payments for operating leases	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (dollars in thousands) Operating Leases ​ Finance Leases ​ Total 2023 ​ $ 252 ​ $ 101 ​ $ 353 2024 ​ 239 ​ 80 ​ 319 2025 ​ 205 ​ 65 ​ 270 2026 ​ 195 ​ ​ 26 ​ 221 Total lease obligations ​ 891 ​ 272 ​ 1,163 Less: Amount representing interest ​ (118) ​ (42) ​ (160) Present value of net minimum lease obligations ​ 773 ​ 230 ​ 1,003 Less, current portion ​ (199) ​ (162) ​ (361) Long term portion ​ $ 574 ​ $ 68 ​ $ 642 ​
Summary of estimated future minimum lease payments for finance leases	As of December 31, 2022, the estimated future minimum lease payments, excluding non-lease components, are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ (dollars in thousands) Operating Leases ​ Finance Leases ​ Total 2023 ​ $ 252 ​ $ 101 ​ $ 353 2024 ​ 239 ​ 80 ​ 319 2025 ​ 205 ​ 65 ​ 270 2026 ​ 195 ​ ​ 26 ​ 221 Total lease obligations ​ 891 ​ 272 ​ 1,163 Less: Amount representing interest ​ (118) ​ (42) ​ (160) Present value of net minimum lease obligations ​ 773 ​ 230 ​ 1,003 Less, current portion ​ (199) ​ (162) ​ (361) Long term portion ​ $ 574 ​ $ 68 ​ $ 642 ​
Schedule of other information	​ ​ ​ ​ ​ ​ December 31, ​ December 31, ​ 2022 ​ 2021 Weighted-average remaining lease term (years): ​ ​ ​ Operating leases 3.7 ​ 4.7 Finance leases 2.8 ​ 3.1 Weighted-average discount rate: ​ ​ ​ Operating leases 8.00% ​ 8.00% Finance leases 10.31% ​ 10.03% ​

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2022
COMMITMENTS AND CONTINGENCIES [Abstract]
Purchase Obligations	​ ​ ​ ​ ​ Years ending December 31, ​ (dollars in thousands) 2023 ​ $ 1,113 2024 ​ 170 2025 ​ 50 ​ ​ $ 1,333 ​

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2022
INCOME TAXES [Abstract]
Schedule of Deferred Tax Assets And Liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Dollars in Thousands ​ 2022 2021 Deferred tax assets: ​ ​ Net operating loss and credit carryforwards ​ $ 18,410 ​ $ 17,604 Allowance for doubtful accounts ​ ​ 371 ​ ​ 403 Stock-based compensation ​ 1,906 ​ 915 Other ​ 140 ​ 127 Gross deferred tax assets ​ 20,827 ​ 19,049 Deferred tax liabilities: ​ ​ Property and equipment ​ (274) ​ (257) Intangible assets ​ (1,950) ​ (3,589) Other ​ (35) ​ (18) Gross deferred tax liabilities ​ (2,259) ​ (3,864) Net deferred tax assets ​ 18,568 ​ 15,185 Less valuation allowance ​ (18,568) ​ (15,185) Net deferred liability ​ $ — ​ $ — ​
Reconciliation of the Provision for Income Taxes	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Dollars in Thousands ​ ​ 2022 ​ 2021 Benefit at federal rate ​ $ (2,563) ​ $ (1,788) Increase (decrease) resulting from: ​ ​ State income taxes—net of federal benefit ​ (747) ​ (289) Miscellaneous permanent differences ​ 51 ​ 62 Warrant liability revaluation ​ (153) ​ (97) Meals and entertainment ​ ​ 32 ​ ​ 19 PPP Loan forgiven ​ ​ — ​ ​ (192) Income taxed to owners on Non-Controlling Interest (NCI) ​ ​ (3) ​ ​ (3) Change in valuation allowance ​ 3,383 ​ 2,288 Total income tax benefit ​ $ — ​ $ — ​
Schedule of Income Taxes by Jurisdiction	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Dollars in Thousands ​ 2022 2021 Federal: ​ ​ Current ​ $ — ​ $ — Deferred ​ — ​ — Total Federal ​ $ — ​ $ — State: ​ ​ Current ​ $ — ​ $ — Deferred ​ — ​ — Total State ​ $ — ​ $ — Foreign: ​ ​ Current ​ $ — ​ $ — Deferred ​ — ​ — Total Foreign ​ $ — ​ $ — Total Tax Provision ​ $ — ​ $ — ​
Summary of Operating Loss Carryforwards	​ ​ ​ ​ ​ ​ ​ Dollars in ​ ​ Thousands ​ 2022 2036 ​ $ 14,277 2037 ​ ​ 13,641 Unlimited life ​ 46,546 Total Federal ​ $ 74,464 ​

STOCKHOLDERS' EQUITY (Tables)

STOCKHOLDERS' EQUITY (Tables)	12 Months Ended
	Dec. 31, 2022
STOCKHOLDERS' EQUITY [Abstract]
Summary of dividends recorded	There were no deemed dividends recorded during the years ended December 31, 2022 and 2021.

FAIR VALUE (Tables)

FAIR VALUE (Tables)	12 Months Ended
	Dec. 31, 2022
FAIR VALUE [Abstract]
Schedule of Changes in Fair Value of Liability	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Dollars in Thousands ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, 2022 ​ ​ ​ ​ ​ ​ ​ Bridge Note ​ ​ ​ ​ Warrant Liabilities Beginning balance at January 1 ​ ​ ​ ​ ​ ​ ​ $ 606 Total losses: ​ ​ ​ ​ ​ ​ ​ Revaluation recognized in earnings ​ ​ ​ ​ ​ ​ ​ ​ (606) Balance at December 31 ​ ​ ​ ​ ​ ​ ​ $ – ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, 2021 ​ ​ 2016 Warrant ​ Bridge Note ​ Total Warrant ​ Liability Warrant Liabilities Liabilities Beginning balance at January 1 ​ $ 130 ​ $ 1,195 ​ $ 1,325 Total losses: ​ ​ ​ Revaluation recognized in earnings ​ ​ – ​ ​ (269) ​ ​ (269) Deductions – warrant exercises and write-offs ​ ​ – ​ ​ (320) ​ ​ (320) Deductions – warrant liability settlement ​ ​ (130) ​ ​ – ​ ​ (130) Balance at December 31 ​ $ – ​ $ 606 ​ $ 606 ​

EQUITY INCENTIVE PLAN (Tables)

EQUITY INCENTIVE PLAN (Tables)	12 Months Ended
	Dec. 31, 2022
EQUITY INCENTIVE PLAN [Abstract]
Summary of stock option activity	The following table summarizes stock option activity under our plans during the year ended December 31, 2022: ​ ​ ​ ​ ​ ​ ​ Number of Weighted-Average ​ ​ Options ​ Exercise Price Outstanding at January 1, 2022 2,635,287 ​ $ 3.38 Granted 1,114,000 ​ 1.51 Forfeited (67,951) ​ 2.18 Outstanding at December 31, 2022 3,681,336 ​ $ 2.84 Exercisable at December 31, 2022 2,167,604 ​ $ 3.24 ​

SALES SERVICE REVENUE, NET AN_2

SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Tables)	12 Months Ended
	Dec. 31, 2022
SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE [Abstract]
Schedule of Net Revenues	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, (dollars in thousands) ​ Diagnostic Testing ​ Biomarker Testing ​ Total ​ 2022 2021 2022 2021 2022 2021 Medicaid ​ $ 50 ​ $ 43 ​ $ — ​ $ — ​ $ 50 ​ $ 43 Medicare ​ 3,831 ​ 3,838 ​ — ​ — ​ 3,831 ​ 3,838 Self-pay ​ 326 ​ 234 ​ — ​ — ​ 326 ​ 234 Third party payers ​ 4,211 ​ 3,612 ​ — ​ — ​ 4,211 ​ 3,612 Contract diagnostics ​ — ​ — ​ — ​ 56 ​ — ​ 56 Service revenue, net ​ $ 8,418 ​ $ 7,727 ​ $ — ​ $ 56 ​ $ 8,418 ​ $ 7,783
Schedule of Gross to Net Sales Adjustments	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, (dollars in thousands) ​ ​ ​ Contractual Allowances and ​ Revenues, net of Contractual ​ ​ Gross Revenues ​ adjustments ​ Allowances and adjustments ​ 2022 2021 2022 2021 2022 2021 Medicaid ​ $ 50 ​ $ 43 ​ $ — ​ $ — ​ $ 50 ​ $ 43 Medicare ​ 3,831 ​ 3,838 ​ — ​ — ​ 3,831 ​ 3,838 Self-pay ​ 326 ​ 234 ​ — ​ — ​ 326 ​ 234 Third party payers ​ 14,681 ​ 12,597 ​ (10,470) ​ (8,985) ​ 4,211 ​ 3,612 Contract diagnostics ​ – ​ 56 ​ — ​ — ​ — ​ 56 ​ ​ 18,888 ​ 16,768 ​ (10,470) ​ (8,985) ​ 8,418 ​ 7,783 Other ​ 1,402 ​ 914 ​ — ​ — ​ 1,402 ​ 914 ​ ​ $ 20,290 ​ $ 17,682 ​ $ (10,470) ​ $ (8,985) ​ $ 9,820 ​ $ 8,697
Schedule of Reported Revenues Net of Collection Allowance	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ For the Year Ended December 31, ​ ​ Revenues, net of ​ ​ ​ (dollars in thousands) ​ Contractual Allowances ​ Allowances for doubtful ​ ​ ​ and adjustments ​ accounts ​ Total ​ 2022 2021 2022 2021 2022 2021 Medicaid ​ $ 50 ​ $ 43 ​ $ (25) ​ $ (5) ​ $ 25 ​ $ 38 Medicare ​ 3,831 ​ 3,838 ​ (110) ​ (58) ​ 3,721 ​ 3,780 Self-pay ​ 326 ​ 234 ​ (19) ​ — ​ 307 ​ 234 Third party payers ​ 4,211 ​ 3,612 ​ (254) ​ 215 ​ 3,957 ​ 3,827 Contract diagnostics ​ — ​ 56 ​ — ​ — ​ — ​ 56 ​ ​ 8,418 ​ 7,783 ​ (408) ​ 152 ​ 8,010 ​ 7,935 Other ​ 1,402 ​ 914 ​ — ​ — ​ 1,402 ​ 914 ​ ​ $ 9,820 ​ $ 8,697 ​ $ (408) ​ $ 152 ​ $ 9,412 ​ $ 8,849
Schedule of Receivables	The following summarizes the mix of receivables as of December 31, 2022 and 2021: ​ ​ ​ ​ ​ ​ ​ (dollars in thousands) December 31, 2022 December 31, 2021 Medicaid ​ $ 34 ​ $ 45 Medicare ​ 1,124 ​ 727 Self-pay ​ 291 ​ 139 Third party payers ​ 1,888 ​ 2,111 Contract diagnostic services and other ​ 53 ​ 159 ​ ​ $ 3,390 ​ $ 3,181 Less allowance for doubtful accounts ​ (2,354) ​ (2,484) Accounts receivable, net ​ $ 1,036 ​ $ 697
Schedule of Allowance for Doubtful Accounts	​ The following table presents the roll-forward of the allowance for doubtful accounts for the year ended December 31, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Allowance for ​ ​ ​ ​ ​ Doubtful (dollars in thousands) ​ ​ ​ ​ Accounts Balance, January 1, 2022 ​ ​ $ (2,484) Collection Allowance: ​ ​ Medicaid ​ $ (25) ​ Medicare ​ (110) ​ Self-pay ​ ​ (19) ​ ​ ​ Third party payers ​ (254) ​ ​ ​ (408) ​ Bad debt expense ​ $ 2 ​ Total charges ​ ​ (406) Other ​ ​ ​ ​ ​ 536 Balance, December 31, 2022 ​ ​ $ (2,354) ​
Schedule of Customer Revenue and Accounts Receivable Concentrations	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net sales ​ ​ Accounts receivable, as of ​ ​ ​ Years Ended ​ ​ ​ ​ ​ ​ December 31, ​ ​ December 31, ​ December 31, ​ ​ ​ 2022 ​ 2021 ​ ​ 2022 ​ 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Customer A ​ * ​ * ​ ​ * ​ 21 % Customer B ​ * ​ * ​ ​ * ​ 12 % Customer C ​ * ​ * ​ ​ 12 % * ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ * represents less than 10% ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

BUSINESS DESCRIPTION (Narrative

BUSINESS DESCRIPTION (Narrative) (Details) - USD ($)		12 Months Ended
	Apr. 02, 2021	Dec. 31, 2022	Dec. 31, 2021	Apr. 30, 2020
Business Acquisition [Line Items]
Net loss		$ 12,178,000	$ 8,517,000
Accumulated deficit		(92,297,000)	(80,094,000)
Working deficiency		1,300,000
Net cash used in operating activities		(7,721,000)	(6,577,000)
Proceeds from issuance of common stock		$ 129,000	$ 16,207,000
Common stock, par value		$ 0.01	$ 0.01
Sales Agreement with Alliance Global Partners
Business Acquisition [Line Items]
Proceeds from issuance of common stock	$ 16,000,000
Sale of common stock	5,119,656
Additional shares available for future sales	$ 6,000,000
Sales Agreement with Alliance Global Partners | Maximum [Member]
Business Acquisition [Line Items]
Proceeds from issuance of common stock	$ 22,000,000
Joint Venture [Member] | Popular Healthcare PLLC [Member]
Business Acquisition [Line Items]
Percentage of interest in joint venture				49%
Joint Venture [Member] | Popular [Member] | Popular Healthcare PLLC [Member]
Business Acquisition [Line Items]
Percentage of interest in joint venture				51%
Joint Venture [Member] | Poplar Put Right [Member] | Scenario, Plan [Member]
Business Acquisition [Line Items]
Price per share				$ 1
Joint Venture [Member] | Poplar Put Right [Member] | Scenario, Plan [Member] | Popular Healthcare PLLC [Member]
Business Acquisition [Line Items]
Percentage of interest in joint venture				100%
Purchase price				$ 51

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Narrative) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets [Line Items]
Prepaid insurance	$ 300	$ 300
Prepaid assets and other receivables	200	200
Inventory Valuation Reserves	$ 0	$ 100
Awards outstanding	0	0
Impairment of intangible assets	$ 0	$ 0
Amortization expense of converted debt issuance costs	100	100
Insurance claims, recoveries	0	0
Income tax, interest and penalties	$ 0	0
Share-based compensation arrangement by share-based payment award, expiration period	10 years
Advertising expense	$ 100	100
Research and development expense	$ 1,700	$ 1,300
Securities not included in the computation of diluted net loss per share	4,487,967	3,584,688
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Stock options, unvested options, vesting period	4 years

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Estimated Useful Lives of Property and Equipment) (Details)	12 Months Ended
	Dec. 31, 2022
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years
Laboratory Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Laboratory Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Computer Equipment and Software [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Computer Equipment and Software [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	7 years

SUMMARY OF SIGNIFICANT ACCOUN_6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (VIE) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Assets:
Accounts receivable, net	$ 1,036	$ 697
Total assets	21,504	30,439
Liabilities:
Accrued expenses	1,584	1,918
Total liabilities	5,137	5,835
Total stockholders' equity	16,367	24,604	$ 14,162
Variable Interest Entity, Primary Beneficiary [Member]
Assets:
Accounts receivable, net	335	180
Total assets	335	180
Liabilities:
Accrued expenses	50	36
Total liabilities	50	36
Noncontrolling Interest in Joint Venture	65	40
Total stockholders' equity	$ 127	$ 79

SUMMARY OF SIGNIFICANT ACCOUN_7

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Outstanding Securities) (Details) - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities not included in the computation of diluted net loss per share	4,487,967	3,584,688
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities not included in the computation of diluted net loss per share	3,681,336	2,635,287
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities not included in the computation of diluted net loss per share	689,131	831,901
Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Securities not included in the computation of diluted net loss per share	117,500	117,500

PROPERTY AND EQUIPMENT, NET (Su

PROPERTY AND EQUIPMENT, NET (Summary of Property and Equipment) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 1,979	$ 1,669
Less-accumulated depreciation and amortization	(1,102)	(833)
Property, Plant and Equipment, Net, Total	877	836
Depreciation expense	300	200
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	24	12
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	931	794
Computer Equipment and Software [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	990	725
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Gross	$ 34	$ 138

INTANGIBLES (Narrative) (Detail

INTANGIBLES (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
INTANGIBLES [Abstract]
Amortization expense for intangible assets	$ 1	$ 1
Amortization expense, 2023	1
Amortization expense, 2024	1
Amortization expense, 2025	1
Amortization expense, 2026	1
Amortization expense, 2027	$ 1

INTANGIBLES (Schedule of Intang

INTANGIBLES (Schedule of Intangible Assets) (Details) - Technology [Member] - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Finite-Lived Intangible Assets, Net [Abstract]
Cost	$ 18,990	$ 18,990
Accumulated Amortization	5,222	4,273
Net Book Value	$ 13,768	$ 14,717

INTANGIBLES (Intangible Assets,

INTANGIBLES (Intangible Assets, Estimated Useful Life) (Details)	12 Months Ended
	Dec. 31, 2022
Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated useful life	20 years

LONG-TERM DEBT (Schedule of Deb

LONG-TERM DEBT (Schedule of Debt) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Total long-term debt	$ 389	$ 186
Current portion of long-term debt	(255)	(26)
Long-term debt, net of current maturities	134	160
Department of Economic and Community Development (DECD)
Debt Instrument [Line Items]
Total long-term debt	176	205
Debt issuance cost	(15)	(19)
Financed Insurance Loan [Member]
Debt Instrument [Line Items]
Total long-term debt	$ 228	$ 0

LONG-TERM DEBT (Narrative) (Det

LONG-TERM DEBT (Narrative) (Details) - USD ($)		12 Months Ended
	Jan. 08, 2018	Dec. 31, 2022	Dec. 31, 2021	Jul. 31, 2022
Debt Instrument [Line Items]
Current maturities of long-term debt, less debt issuance costs		$ 255,000	$ 26,000
Department of Economic and Community Development (DECD)
Debt Instrument [Line Items]
Debt instrument, term	10 years
Debt instrument, maturity date	Dec. 31, 2027
Interest rate (as a percent)	3.25%
Financed Insurance Loan [Member]
Debt Instrument [Line Items]
Interest rate (as a percent)				5.99%
Debt instrument, face amount				$ 400,000
Term loan | Department of Economic and Community Development (DECD)
Debt Instrument [Line Items]
Proceeds from long-term debt	$ 300,000
Debt issuance costs, net	$ 31,000	15,000	19,000
Amortization of debt issuance cost		4,000	$ 3,000
2023		3,000
2024		3,000
2025		3,000
2026		3,000
2027		$ 3,000

LONG-TERM DEBT (Financed Insura

LONG-TERM DEBT (Financed Insurance Loan) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Jul. 31, 2022	Dec. 31, 2021
Debt Instrument [Line Items]
Total debt	$ 389		$ 186
Financed Insurance Loan [Member]
Debt Instrument [Line Items]
Debt instrument, face amount		$ 400
Interest rate (as a percent)		5.99%
Total debt	$ 228		0
Minimum [Member] | Financed Insurance Loan [Member]
Debt Instrument [Line Items]
Total debt			$ 200

LONG-TERM DEBT (Paycheck Protec

LONG-TERM DEBT (Paycheck Protection Program.) (Details) - USD ($)	Dec. 31, 2022	Apr. 23, 2020
Debt Instrument [Line Items]
Long-term Debt	$ 404,000
Unsecured Debt [Member] | Paycheck Protection Program | Promissory notes
Debt Instrument [Line Items]
Debt instrument, face amount		$ 787,200

LONG-TERM DEBT (Aggregate Futur

LONG-TERM DEBT (Aggregate Future Maturities on Long-Term Debt) (Details) $ in Thousands	Dec. 31, 2022 USD ($)
Debt Instrument [Line Items]
2023	$ 258
2024	31
2025	32
2026	33
2027	34
2028 and thereafter	16
Total	404
Department of Economic and Community Development (DECD)
Debt Instrument [Line Items]
2023	30
2024	31
2025	32
2026	33
2027	34
2028 and thereafter	16
Total	176
Financed Insurance Loan [Member]
Debt Instrument [Line Items]
2023	228
Total	$ 228

ACCRUED EXPENSES OTHER CURREN_3

ACCRUED EXPENSES OTHER CURRENT LIABILITIES (Accrued Expenses) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
ACCRUED EXPENSES OTHER CURRENT LIABILITIES [Abstract]
Accrued expenses	$ 983	$ 1,033
Accrued compensation	491	718
Accrued franchise, property and sales and use taxes	91	148
Accrued interest	19	19
Accrued expenses	$ 1,584	$ 1,918

ACCRUED EXPENSES OTHER CURREN_4

ACCRUED EXPENSES OTHER CURRENT LIABILITIES (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
ACCRUED EXPENSES OTHER CURRENT LIABILITIES [Abstract]
Reduction in Certain Accrued Expense and Accounts Payable	$ 0.1	$ 0.1

LEASES - Narrative (Details)

LEASES - Narrative (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($) item	Dec. 31, 2021 USD ($)	Nov. 29, 2021 USD ($)
Lessee, Lease, Description [Line Items]
Operating leases	$ 200	$ 200
Operating lease right-of-use assets obtained in exchange for operating lease obligations	92	771
Operating lease right-of-use assets, net	763	858	$ 800
Operating Lease, Liability, Noncurrent	574	697	$ 800
Finance lease ROU assets	114	94
Net investment in leased assets	$ 100
Minimum [Member]
Lessee, Lease, Description [Line Items]
Facility leases | item	1
Renewal term	1 year
Maximum [Member]
Lessee, Lease, Description [Line Items]
Renewal term	5 years
Net investment in leased assets		200
Right of Use Asset
Lessee, Lease, Description [Line Items]
Finance lease ROU assets	$ 0	$ 100

LEASES - Operating and Financin

LEASES - Operating and Financing leases (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Nov. 29, 2021
Balance sheet presentation of our operating and financing leases
Operating lease right-of-use assets, net	$ 763	$ 858	$ 800
Finance lease right-of-use assets, net	257	371
Total lease assets	1,020	1,229
Current maturities of operating lease liabilities	199	166
Current maturities of finance lease liabilities	162	222
Operating lease liabilities, less current maturities	574	697	$ 800
Finance lease liabilities, less current maturities	68	159
Total lease liabilities	1,003	1,244
HemeScreen Reagent Rental [Member]
Balance sheet presentation of our operating and financing leases
Finance lease right-of-use assets, net	$ 13	$ 61

LEASES - Future Minimum Lease P

LEASES - Future Minimum Lease Payments (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021	Nov. 29, 2021
Operating leases, estimated future minimum lease payments
2023	$ 252
2024	239
2025	205
2026	195
Total lease obligations	891
Less: Amount representing interest	(118)
Present value of net minimum lease obligations	773
Less, current portion	(199)	$ (166)
Long term portion	574	697	$ 800
Finance leases, estimated future minimum lease payments
2023	101
2024	80
2025	65
2026	26
Total lease obligations	272
Less: Amount representing interest	(42)
Present value of net minimum lease obligations	230
Less, current portion	(162)	(222)
Long term portion	68	159
2023	353
2024	319
2025	270
2026	221
Total lease obligations	1,163
Less: Amount representing interest	(160)
Total lease liabilities	1,003	$ 1,244
Less, current portion	(361)
Long term portion	$ 642

LEASES - Other Information (Det

LEASES - Other Information (Details)	Dec. 31, 2022	Dec. 31, 2021
LEASES [Abstract]
Operating leases (in years)	3 years 8 months 12 days	4 years 8 months 12 days
Finance leases (in years)	2 years 9 months 18 days	3 years 1 month 6 days
Operating leases discount rate	8%	8%
Finance leases discount rate	10.31%	10.03%

LEASES - Operating and Financ_2

LEASES - Operating and Financing Lease Cost (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Lessee, Lease, Description [Line Items]
Operating lease costs	$ 0.3	$ 0.3
Maximum [Member]
Lessee, Lease, Description [Line Items]
Short-term lease costs	0.1	0.1
Finance leases, amortization expense and interest	$ 0.1	$ 0.1

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Narrative) (Details) - USD ($) $ in Thousands	Feb. 06, 2017	Dec. 31, 2022	Dec. 31, 2021
Loss Contingencies [Line Items]
Class of Warrant or Right, Outstanding			357
Outstanding debt		$ 404
CPA Global
Loss Contingencies [Line Items]
Loss contingency, damages sought	$ 200
CPA Global | Minimum [Member]
Loss Contingencies [Line Items]
Loss contingency accrual		$ 100	$ 100

COMMITMENTS AND CONTINGENCIES_3

COMMITMENTS AND CONTINGENCIES (Purchase Commitments) (Details) - Inventories [Member]	Dec. 31, 2022 USD ($)
2023	$ 1,113
2024	170
2025	50
Total	$ 1,333

INCOME TAXES (Narrative) (Detai

INCOME TAXES (Narrative) (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Increase in valuation allowance	$ 3.4	$ 1.7
Deferred Tax Assets, Net of Valuation Allowance	18.6	$ 15.2
Federal
Gross federal and state net operating loss ("NOL") carryforwards	74
State and Local Jurisdiction [Member]
Gross federal and state net operating loss ("NOL") carryforwards	$ 2.4

INCOME TAXES (Schedule of Defer

INCOME TAXES (Schedule of Deferred Tax Assets And Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
INCOME TAXES [Abstract]
Net operating loss and credit carryforwards	$ 18,410	$ 17,604
Allowance for doubtful accounts	371	403
Stock-based compensation	1,906	915
Other	140	127
Gross deferred tax assets	20,827	19,049
Property and equipment	(274)	(257)
Intangible assets	(1,950)	(3,589)
Other	(35)	(18)
Gross deferred tax liabilities	(2,259)	(3,864)
Net deferred tax assets	18,568	15,185
Less valuation allowance	(18,568)	(15,185)
Net deferred liability	$ 0	$ 0

INCOME TAXES (Reconciliation of

INCOME TAXES (Reconciliation of the Provision for Income Taxes) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
INCOME TAXES [Abstract]
Benefit at federal rate	$ (2,563)	$ (1,788)
State income taxes-net of federal benefit	(747)	(289)
Miscellaneous permanent differences	51	62
Warrant liability revaluation	(153)	(97)
Meals and entertainment	32	19
PPP Loan forgiven		(192)
Income taxed to owners on Non-Controlling Interest (NCI)	(3)	(3)
Change in valuation allowance	3,383	2,288
Income Tax Expense (Benefit), Total	$ 0	$ 0

INCOME TAXES (Schedule of Incom

INCOME TAXES (Schedule of Income Taxes by Jurisdiction) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
INCOME TAXES [Abstract]
Income Tax Expense (Benefit), Total	$ 0	$ 0

INCOME TAXES (Summary of Operat

INCOME TAXES (Summary of Operating Loss Carryforwards) (Details) - Federal $ in Millions	Dec. 31, 2022 USD ($)
Tax Years 2036 Through 2037 [Member]
Operating Loss Carryforwards	$ 28
Unlimited life
Operating Loss Carryforwards	47
Internal Revenue Service (IRS) [Member]
Operating Loss Carryforwards	74,464
Internal Revenue Service (IRS) [Member] | Tax Year 2036 [Member]
Operating Loss Carryforwards	14,277
Internal Revenue Service (IRS) [Member] | Tax Year 2037 [Member]
Operating Loss Carryforwards	13,641
Internal Revenue Service (IRS) [Member] | Unlimited life
Operating Loss Carryforwards	$ 46,546

STOCKHOLDERS' EQUITY (Common St

STOCKHOLDERS' EQUITY (Common Stock, 2018 Purchase Agreement and LP Purchase Agreement) (Details) - USD ($)		12 Months Ended
	Mar. 26, 2020	Dec. 31, 2022	Dec. 31, 2021	Dec. 20, 2018	Dec. 19, 2018
Class of Stock [Line Items]
Common stock, shares authorized (in shares)		150,000,000	150,000,000		150,000,000
Proceeds from exercise of warrants		$ 11,000	$ 400,000
Proceeds upon issuance of common stock from exercise of stock options			3,000
Issuance of common stock in connection with at the market offering, net of issuance costs		$ 129,000	$ 14,947,000
Shares issued (in shares)		22,820,260	22,708,442
Common stock, shares outstanding (in shares)		22,820,260	22,708,442
Issuance of common stock, net of issuance costs		$ 129,000	$ 16,207,000
Issuance of common stock for consulting services			$ 150,000
Common Stock [Member]
Class of Stock [Line Items]
Proceeds upon issuance of common stock from exercise of warrants (in shares)		26,795	74,000
Proceeds upon issuance of common stock from exercise of stock options (in shares)			1,379
Issuance of common stock in connection with at the market offering, net of issuance costs		$ 1,000	$ 45,000
Shares issued (in shares)		85,023	4,501,000
Issuance of common stock for consulting services (in shares)			55,147
Common Stock [Member]
Class of Stock [Line Items]
Common stock issued for exercise of warrants		26,795	74,000
Warrant exercises in period		26,795
Proceeds from exercise of warrants			$ 400,000
Proceeds upon issuance of common stock from exercise of stock options			$ 3,000
Proceeds upon issuance of common stock from exercise of stock options (in shares)			1,379
Issuance of common stock for consulting services (in shares)			55,147
Issuance of common stock for consulting services			$ 200,000
Preferred Class B
Class of Stock [Line Items]
Conversion price (in dollars per share)		$ 0.40
Lincoln Park [Member]
Class of Stock [Line Items]
Shares issued (in shares)			500,000
Issuance of common stock, net of issuance costs			$ 1,300,000
Maximum [Member] | Common Stock [Member]
Class of Stock [Line Items]
Proceeds from exercise of warrants		$ 100,000
Per Proposal To Increase Authorized Shares [Member]
Class of Stock [Line Items]
Common stock, shares authorized (in shares)				250,000,000
LP 2020 Purchase Agreement [Member]
Class of Stock [Line Items]
Purchase agreement term		24 months
LP 2020 Purchase Agreement [Member] | Lincoln Park [Member]
Class of Stock [Line Items]
Issuance of common stock in connection with at the market offering, net of issuance costs	$ 10,000,000

STOCKHOLDERS' EQUITY (At The Ma

STOCKHOLDERS' EQUITY (At The Market Offering Agreement) (Details) - USD ($) $ / shares in Units, $ in Thousands		3 Months Ended	12 Months Ended		24 Months Ended
	Apr. 02, 2021	Mar. 31, 2023	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2022	Apr. 13, 2020
Class of Stock [Line Items]
Common stock, par value			$ 0.01	$ 0.01	$ 0.01
Proceeds from issuance of common stock			$ 129	$ 16,207
AGP
Class of Stock [Line Items]
Aggregate sales proceeds of common stock					$ 15,500
Payments of Stock Issuance Costs					$ 500
Shares issued (in shares)					5,119,656
AGP | At The Market Offering Agreement
Class of Stock [Line Items]
Common stock, par value	$ 0.01
Aggregate sales proceeds of common stock	$ 22,000
Aggregate authorized offering price						$ 50,000
Percentage of cash fee	3%
Proceeds from issuance of common stock			$ 100	$ 14,900
Shares issued (in shares)			85,023	4,501,000
Subsequent Events [Member] | AGP
Class of Stock [Line Items]
Aggregate sales proceeds of common stock		$ 400
Shares issued (in shares)		533,633

STOCKHOLDERS' EQUITY (Preferred

STOCKHOLDERS' EQUITY (Preferred Stock) (Details) - shares	Dec. 31, 2022	Dec. 31, 2021
STOCKHOLDERS' EQUITY [Abstract]
Preferred stock, shares authorized (in shares)	15,000,000	15,000,000

STOCKHOLDERS' EQUITY (Series B

STOCKHOLDERS' EQUITY (Series B Preferred Stock) (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Aug. 25, 2017
Class of Stock [Line Items]
Preferred stock, par value (in dollars per share)	$ 0.01
Warrants outstanding (in shares)		357
Proceeds from issuance of warrants	$ 11	$ 400
Preferred stock, shares authorized (in shares)	15,000,000	15,000,000
Preferred stock, shares outstanding (in shares)	47	47
Preferred stock, shares issued (in shares)	47	47
Preferred Class B
Class of Stock [Line Items]
Preferred stock, par value (in dollars per share)			$ 0.01
Conversion price (in dollars per share)	$ 0.40
Number of shares converted (in shares)	0	0
Preferred stock, shares authorized (in shares)	6,900	6,900	6,900
Preferred stock, shares outstanding (in shares)	47	47
Preferred Stock, Liquidation Preference Per Share	$ 1,000		$ 1,000
Number of common shares issuable upon conversion of preferred stock.	117,500

STOCKHOLDERS' EQUITY (Schedule

STOCKHOLDERS' EQUITY (Schedule of Warrants) (Details) - USD ($) $ / shares in Units, $ in Millions	1 Months Ended	12 Months Ended
	Jan. 31, 2021	Dec. 31, 2022	Dec. 31, 2021
Class of Stock [Line Items]
Underlying shares (in shares)		689,131
Warrants expired		115,975	239
Warrants outstanding (in shares)			357
Settlement of warrant liability			$ 0.1
Warrants Not Assumed In Merger, Expiring April 2023 Group A [Member]
Class of Stock [Line Items]
Underlying shares (in shares)		148,378
Exercise price (in dollars per share)		$ 5.40
Warrants Not Assumed In Merger, Expiring July 2023 Group A [Member]
Class of Stock [Line Items]
Underlying shares (in shares)		29,343
Exercise price (in dollars per share)		$ 5.40
Warrants Not Assumed In Merger, Expiring August 2023 Group A [Member]
Class of Stock [Line Items]
Underlying shares (in shares)		41,806
Exercise price (in dollars per share)		$ 5.40
Warrants Not Assumed In Merger, Expiring September 2023 Group A [Member]
Class of Stock [Line Items]
Underlying shares (in shares)		40,719
Exercise price (in dollars per share)		$ 5.40
Warrants Not Assumed In Merger, Expiring November 2023 [Member]
Class of Stock [Line Items]
Underlying shares (in shares)		75,788
Exercise price (in dollars per share)		$ 5.40
Warrants Not Assumed In Merger, Expiring December 2023 [Member]
Class of Stock [Line Items]
Underlying shares (in shares)		51,282
Exercise price (in dollars per share)		$ 5.40
Warrants Not Assumed In Merger, Expiring April 2024 [Member]
Class of Stock [Line Items]
Underlying shares (in shares)		147,472
Exercise price (in dollars per share)		$ 5.40
Warrants Not Assumed In Merger, Expiring May 2024 [Member]
Class of Stock [Line Items]
Underlying shares (in shares)		154,343
Exercise price (in dollars per share)		$ 9.56
2016 Warrant Liability [Member]
Class of Stock [Line Items]
Warrants outstanding (in shares)	357		0
Settlement of warrant liability	$ 0.1

STOCKHOLDERS' EQUITY (Offering

STOCKHOLDERS' EQUITY (Offering Warrants) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Class of Stock [Line Items]
Deemed dividend	$ 0	$ 0
Warrants exercised	26,795	74,000
Proceeds from issuance of warrants	$ 11	$ 400
Intrinsic value of warrants exercised in period		$ 100
Maximum [Member]
Class of Stock [Line Items]
Intrinsic value of warrants exercised in period	$ 100

STOCKHOLDERS' EQUITY (Note Conv

STOCKHOLDERS' EQUITY (Note Conversion Warrants) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Equity [Abstract]
Deemed dividend	$ 0	$ 0

STOCKHOLDERS' EQUITY (Convertib

STOCKHOLDERS' EQUITY (Convertible Promissory Note Warrants) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Equity [Abstract]
Deemed dividend	$ 0	$ 0

STOCKHOLDERS' EQUITY (Remaining

STOCKHOLDERS' EQUITY (Remaining Warrants) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
STOCKHOLDERS' EQUITY [Abstract]
Class of warrant, number of securities called by warrants	689,131
Warrants exercised	26,795	74,000
Proceeds from issuance of warrants	$ 11	$ 400

STOCKHOLDERS' EQUITY (Deemed Di

STOCKHOLDERS' EQUITY (Deemed Dividends) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Equity [Abstract]
Amount Recorded	$ 0	$ 0

FAIR VALUE (Narratives) (Detail

FAIR VALUE (Narratives) (Details) $ in Millions	1 Months Ended	12 Months Ended
	Jan. 31, 2021 USD ($) shares	Dec. 31, 2022 Y shares	Dec. 31, 2021 USD ($) Y shares
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants outstanding (in shares)			357
Settlement of warrant liability | $			$ 0.1
Warrants exercised		26,795	74,000
2016 Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants outstanding (in shares)	357		0
Settlement of warrant liability | $	$ 0.1
Bridge Note Warrant Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liabilities written off | $			$ 0.3
Warrants exercised			74,000
Minimum [Member] | Measurement Input, Price Volatility [Member] | Bridge Note Warrant Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants and Rights Outstanding, Measurement Input		69	61
Minimum [Member] | Measurement Input, Risk Free Interest Rate [Member] | Bridge Note Warrant Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants and Rights Outstanding, Measurement Input		4.42	0.06
Minimum [Member] | Measurement Input, Expected Term [Member] | Bridge Note Warrant Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants and Rights Outstanding, Measurement Input | Y		0.3	0.3
Maximum [Member] | Measurement Input, Price Volatility [Member] | Bridge Note Warrant Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants and Rights Outstanding, Measurement Input		77	199
Maximum [Member] | Measurement Input, Risk Free Interest Rate [Member] | Bridge Note Warrant Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants and Rights Outstanding, Measurement Input		4.76	0.73
Maximum [Member] | Measurement Input, Expected Term [Member] | Bridge Note Warrant Liabilities [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants and Rights Outstanding, Measurement Input | Y		1.41	2.4

FAIR VALUE (Schedule of Changes

FAIR VALUE (Schedule of Changes in Fair Value of Liability) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 606	$ 1,325
Total losses:
Revaluation recognized in earnings	(606)	(269)
Deductions - warrant exercises and write-offs		(320)
Deductions - warrant liability settlement		(130)
Balance at end of period		606
2016 Warrant Liability [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance		130
Total losses:
Deductions - warrant liability settlement		(130)
Bridge Note Warrant Liabilities [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 606	1,195
Total losses:
Revaluation recognized in earnings		(269)
Deductions - warrant exercises and write-offs		(320)
Balance at end of period		$ 606

EQUITY INCENTIVE PLAN (Narrativ

EQUITY INCENTIVE PLAN (Narrative) (Details) - USD ($) $ / shares in Units, $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, expiration period	10 years
Stock-based compensation	$ 3.8	$ 1.9
Unvested stock options, unrecognized compensation expense weighted average recognition period	2 years 7 months 6 days
Unrecognized compensation expense related to unvested stock awards	$ 3.1
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)	1,114,000	1,907,347
Granted (in dollars per share)	$ 1.51	$ 2.89
Forfeited (in shares)	(67,951)	(93,673)
Forfeited (in dollars per share)	$ 2.18	$ 2.82
Weighted average grant date fair value (in dollars per share)	$ 1.45
Exercised (in shares)		1,379
Options exercised, weighted average exercise price		$ 2.06
Risk free interest rate, minimum	1.60%
Risk free interest rate, maximum	3.55%
Term	6 years
Stock options, expected to vest, outstanding (in shares)	3,295,639
Stock options, expected to vest remaining contractual term	8 years 2 months 12 days
Minimum [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility rate	166%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, unvested options, vesting period	4 years
Maximum [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options, unvested options, vesting period	4 years
Volatility rate	167%
Equity Incentive Plan 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized	3,852,853
Shares available for grant	170,218
Percentage of annual increase in number of shares authorized for grant	5%
Number of additional shares authorized	1,135,422
Equity Incentive Plan 2017 [Member] | Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, expiration period	10 years

EQUITY INCENTIVE PLAN (Summary

EQUITY INCENTIVE PLAN (Summary of Stock Option Activity) (Details) - Stock Options [Member] - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Number of Options
Outstanding at beginning of period (in shares)	2,635,287
Granted (in shares)	1,114,000	1,907,347
Exercised (in shares)		(1,379)
Forfeited (in shares)	(67,951)	(93,673)
Outstanding at end of period (in shares)	3,681,336	2,635,287
Exercisable at end of period (in shares)	2,167,604
Weighted-Average Exercise Price
Outstanding at beginning of period (in dollars per share)	$ 3.38
Granted (in dollars per share)	1.51	$ 2.89
Exercised (in dollars per share)		2.06
Forfeited (in dollars per share)	2.18	2.82
Outstanding at end of period (in dollars per share)	2.84	$ 3.38
Exercisable at end of period (in dollars per share)	$ 3.24

SALES SERVICE REVENUE, NET AN_3

SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Narrative) (Details)	12 Months Ended
	Dec. 31, 2022 USD ($) segment	Dec. 31, 2021 USD ($)
SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE [Abstract]
Number of segments | segment	1
Revenue from sales-type leases	$ 0	$ 200,000
Deferred revenue	$ 119,000	$ 18,000

SALES SERVICE REVENUE, NET AN_4

SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Net Revenues) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	$ 9,820	$ 8,697
Service revenue, net [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	8,418	7,783
Medicaid [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	50	43
Medicaid [Member] | Diagnostic Testing [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	50	43
Medicare [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	3,831	3,838
Medicare [Member] | Diagnostic Testing [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	3,831	3,838
Self-Pay
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	326	234
Self-Pay | Diagnostic Testing [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	326	234
Third-Party Payor [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	4,211	3,612
Third-Party Payor [Member] | Diagnostic Testing [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	4,211	3,612
Contract Diagnostic Services [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments		56
Contract Diagnostic Services [Member] | Biomarker Testing and Clinical Project Services [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments		56
Services Revenue, Net [Member] | Service revenue, net [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	8,418	7,783
Services Revenue, Net [Member] | Diagnostic Testing [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	$ 8,418	7,727
Services Revenue, Net [Member] | Biomarker Testing and Clinical Project Services [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments		$ 56

SALES SERVICE REVENUE, NET AN_5

SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Gross to Net Sales Adjustments) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Gross revenue	$ 20,290	$ 17,682
Contractual allowance and adjustments	(10,470)	(8,985)
Service revenue, net	9,820	8,697
Medicaid [Member]
Disaggregation of Revenue [Line Items]
Gross revenue	50	43
Service revenue, net	50	43
Medicare [Member]
Disaggregation of Revenue [Line Items]
Gross revenue	3,831	3,838
Service revenue, net	3,831	3,838
Self-Pay
Disaggregation of Revenue [Line Items]
Gross revenue	326	234
Service revenue, net	326	234
Third-Party Payor [Member]
Disaggregation of Revenue [Line Items]
Gross revenue	14,681	12,597
Contractual allowance and adjustments	(10,470)	(8,985)
Service revenue, net	4,211	3,612
Contract Diagnostic Services [Member]
Disaggregation of Revenue [Line Items]
Gross revenue		56
Service revenue, net		56
Service revenue, net [Member]
Disaggregation of Revenue [Line Items]
Gross revenue	18,888	16,768
Contractual allowance and adjustments	(10,470)	(8,985)
Service revenue, net	8,418	7,783
Other [Member]
Disaggregation of Revenue [Line Items]
Gross revenue	1,402	914
Service revenue, net	$ 1,402	$ 914

SALES SERVICE REVENUE, NET AN_6

SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Sales, Net of Collection Allowance) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	$ 9,820	$ 8,697
Adjustment for allowance for doubtful accounts	(408)	152
Net sales	9,412	8,849
Medicaid [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	50	43
Adjustment for allowance for doubtful accounts	(25)	(5)
Net sales	25	38
Medicare [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	3,831	3,838
Adjustment for allowance for doubtful accounts	(110)	(58)
Net sales	3,721	3,780
Self-Pay
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	326	234
Adjustment for allowance for doubtful accounts	(19)
Net sales	307	234
Third-Party Payor [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	4,211	3,612
Adjustment for allowance for doubtful accounts	(254)	215
Net sales	3,957	3,827
Contract Diagnostic Services [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments		56
Net sales		56
Service revenue, net [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	8,418	7,783
Adjustment for allowance for doubtful accounts	(408)	152
Net sales	8,010	7,935
Other [Member]
Disaggregation of Revenue [Line Items]
Revenue, net of contractual allowances and adjustments	1,402	914
Net sales	$ 1,402	$ 914

SALES SERVICE REVENUE, NET AN_7

SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Receivables) (Details) - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Accounts receivable, gross	$ 3,390	$ 3,181
Less allowance for doubtful accounts	(2,354)	(2,484)
Accounts receivable, net	1,036	697
Medicaid [Member]
Accounts receivable, gross	34	45
Medicare [Member]
Accounts receivable, gross	1,124	727
Self-Pay
Accounts receivable, gross	291	139
Third-Party Payor [Member]
Accounts receivable, gross	1,888	2,111
Contract Diagnostic Services [Member]
Accounts receivable, gross	$ 53	$ 159

SALES SERVICE REVENUE, NET AN_8

SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Allowance for Doubtful Accounts) (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Allowance for doubtful accounts, Beginning balance	$ (2,484)
Adjustment for allowance for doubtful accounts	(408)	$ 152
Bad debt expense	2
Write-offs	536
Total charges	406
Allowance for doubtful accounts, Ending balance	(2,354)	(2,484)
Medicaid [Member]
Adjustment for allowance for doubtful accounts	(25)	(5)
Medicare [Member]
Adjustment for allowance for doubtful accounts	(110)	(58)
Third-Party Payor [Member]
Adjustment for allowance for doubtful accounts	(254)	$ 215
Self-Pay [Member]
Adjustment for allowance for doubtful accounts	$ (19)

SALES SERVICE REVENUE, NET AN_9

SALES SERVICE REVENUE, NET AND ACCOUNTS RECEIVABLE (Schedule of Customer Revenue and Accounts Receivable Concentrations) (Details) - Accounts Receivable [Member] - Customer Concentration Risk [Member]	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Customer A [Member]
Concentration Risk [Line Items]
Concentration risk, percentage		21%
Customer B [Member]
Concentration Risk [Line Items]
Concentration risk, percentage		12%
Customer C [Member]
Concentration Risk [Line Items]
Concentration risk, percentage	12%

SUBSEQUENT EVENTS (Details)

SUBSEQUENT EVENTS (Details) - Subsequent Events [Member] - Factoring And Security Agreement [Member] - Culain Capital Funding, LLC [Member]	Mar. 27, 2023 USD ($)
Subsequent Event [Line Items]
Purchased receivables	$ 2,000,000
Percentage of sale on accounts receivable	85%
Percentage of initial discount rate	1.25%
Fixed discount period	30 days
Percent of variable fee payable	0.042%
Term of agreement	12 months
Renewal term	12 months
Termination notice period	60 days
Purchased receivable limit	$ 2,000,000
Purchase receivable limit, Multiplier	1.25